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Inflammation-associated pathways are active in intestinal epithelial cells (IECs) and 
contribute to the pathogenesis of colorectal cancer (CRC). Calcineurin, a phosphatase 
required for the activation of the nuclear factor of activated T cells (NFAT) family of 
transcription factors, shows increased expression in CRC. We therefore investigated the 
role of calcineurin in intestinal tumor development. We demonstrate that calcineurin 
and NFAT factors are constitutively expressed by primary IECs and selectively 
activated in intestinal tumors as a result of impaired stratification of the tumor-
associated microbiota and toll-like receptor signaling. Epithelial calcineurin supports 
the survival and proliferation of cancer stem cells in an NFAT-dependent manner and 
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promotes the development of intestinal tumors in mice. Moreover, somatic mutations 
that have been identified in human CRC are associated with constitutive activation of 
calcineurin, whereas nuclear translocation of NFAT is associated with increased death 
from CRC. These findings highlight an epithelial cell–intrinsic pathway that integrates 
signals derived from the commensal microbiota to promote intestinal tumor 
development. 
Intestinal inflammation as observed in inflammatory bowel disease (IBD) is a risk factor for 
the development of CRC1. Increasing evidence suggests that inflammation-associated 
pathways also contribute to CRC development in the absence of clinically overt intestinal 
inflammation1. Thus, signaling pathways with central roles in myeloid and lymphoid cells, 
such as those associated with signal transducer and activator of transcription 3 (STAT3) and 
nuclear factor (NF)-κB, are also active in the transformed intestinal epithelium and promote 
tumor development2–6. 
Calcineurin is a phosphatase with central functions in immunity, many of which are 
elicited by dephosphorylation and activation of NFAT transcription factors7 (which we 
collectively refer to as NFAT). In accordance with an important role of calcineurin in 
immunity, calcineurin inhibitors are widely used to suppress undesired immune responses, 
particularly in solid organ transplantation. The pharmacological inhibition of calcineurin 
therefore leads to an increase in the incidence of solid cancers including CRC, presumably as 
a consequence of impaired calcineurin-dependent tumor immunosurveillance8,9. In contrast to 
these in vivo observations, the blockade of calcineurin and NFAT in isolated CRC cell lines in 
vitro inhibits, rather than promotes, CRC cell growth10–13, thus raising the question of whether 
epithelial calcineurin and NFAT exhibit cell-intrinsic oncogenic roles in CRC. Here we show 
that calcineurin and NFAT are constitutively expressed by IECs and undergo toll-like receptor 
(TLR)-induced activation in response to impaired stratification of the tumor-associated 
microbiota and increased TLR expression by tumor cells. Epithelial calcineurin promotes 
intestinal tumor development through the regulation of cancer stem cell function in mice, and 
its activation in human CRC is associated with increased death from CRC. 
RESULTS 
Epithelial calcineurin promotes intestinal tumor development 
To investigate the role of epithelial calcineurin in intestinal tumor development, we generated 
mice with an IEC-specific deletion of the regulatory B1 subunit of calcineurin (Cnb1; 
encoded by Ppp3r1), which is required for calcineurin activation, using loxP-flanked 
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(‘floxed’) alleles of Ppp3r1 and Cre-mediated deletion (villin-Cre;Ppp3r1fl/fl mice; hereafter 
referred to as Cnb1∆IEC mice). Cnb1∆IEC mice were crossed with ApcMin/+ mice14, which have 
one mutated allele of the adenomatosis polyposis coli (Apc) gene and are a model for 
genetically induced intestinal tumors. The IEC-specific loss of Cnb1 (Supplementary Fig. 
1a,b) did not affect epithelial differentiation (Supplementary Fig. 1c,d), but it was associated 
with reduced intestinal tumor multiplicity and size, as compared to villin-Cre–negative wild-
type (WT) littermates (Ppp3r1fl/fl;ApcMin/+ mice, hereafter referred to as Cnb1WT;ApcMin/+ 
mice; Fig. 1a,b and Supplementary Fig. 1e). Early-stage lesions, such as microadenomas, 
were also reduced in Cnb1∆IEC;ApcMin/+ mice, consistent with calcineurin-dependent 
regulation of tumor initiation (Supplementary Fig. 1f). Furthermore, deletion of Ppp3r1 in 
established tumors of 12-week-old villin-CreERT2;Ppp3r1fl/fl;ApcMin/+, a model with 
tamoxifen-inducible, IEC-specific deletion of Ppp3r1 which we refer to as Cnb1ind∆IEC mice, 
was associated with decreased tumor size, in accordance with calcineurin-dependent tumor 
growth (Fig. 1c and Supplementary Fig. 1g). Tumor multiplicity and size were also reduced 
in Cnb1∆IEC mice treated with colitis-inducing dextran sulfate sodium (DSS) in conjunction 
with the carcinogen azoxymethane (AOM) (Fig. 1d,e and Supplementary Fig. 1h), despite 
an increase in body weight loss and an increase in the disease activity index (Supplementary 
Fig. 1i–k). Thus, the tumor-promoting effects of epithelial calcineurin extend to the colon and 
to colitis-associated CRC. These results demonstrate that epithelial calcineurin supports 
intestinal tumor initiation and growth in mice. 
We next addressed the mechanisms underlying calcineurin-dependent tumor 
development. Because tumorigenesis in ApcMin/+ mice recapitulates central steps of early 
intestinal tumor development in humans and occurs in the absence of clinically overt 
intestinal inflammation, similar to what is observed in the majority of human CRCs, we 
focused on the ApcMin/+ model for subsequent mechanistic studies. Epithelial proliferation was 
reduced and apoptosis was increased in Cnb1-deficient adenomas and microadenomas, 
whereas senescence was not observed (Fig. 1f,g, Supplementary Fig. 2a,b and data not 
shown (K.P.)). Cnb1-dependent regulation of proliferation and apoptosis was not observed in 
normal IECs of Cnb1∆IEC;ApcWT mice and was thus specific for the tumor-associated 
epithelium (Supplementary Fig. 2c,d). These data suggest that calcineurin supports intestinal 
tumor development through promotion of epithelial proliferation and inhibition of apoptosis. 
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Tumor-promoting effects of calcineurin are mediated by NFAT 
To identify the molecular mediators of calcineurin-dependent tumor growth, we investigated 
the role of the NFAT family of transcription factors, of which NFATc1, NFATc2, NFATc3 
and NFATc4 are dependent on calcineurin for dephosphorylation and nuclear translocation7. 
NFATc3 was consistently expressed in primary human CRC and CRC cell lines, whereas 
other calcineurin-dependent NFAT members showed weak and inconsistent expression in 
CRC, with occasional detection of NFATc1 in tumor-infiltrating cells but not in epithelial 
cells (Fig. 2a,b). In mice, normal small intestinal epithelium showed exclusive expression of 
NFATc3 (Supplementary Fig. 3a and data not shown (K.P.)). ApcMin/+ tumors demonstrated 
increased Nfatc3 expression, as compared to normal mucosa, but weak expression of Nfatc1, 
Nfatc2 and Nfatc4 (Fig. 2c,d and Supplementary Fig. 3b). Consistent with calcineurin-
dependent regulation of apoptosis and proliferation in tumors but not in normal epithelium 
(Fig. 1f,g and Supplementary Fig. 2c,d), NFATc3 was cytoplasmic in normal IECs but 
showed calcineurin-dependent nuclear translocation in ApcMin/+ tumors (Fig. 2e). Thus, 
NFATc3 is constitutively expressed by IECs, whereas its calcineurin-dependent activation is 
specific to intestinal tumors. 
To address whether NFATc3 promotes tumor development downstream of 
calcineurin, we investigated mice with an IEC-specific deletion of Nfatc3 (villin-
Cre;Nfatc3fl/fl; hereafter referred to as Nfatc3∆IEC mice). Both in the ApcMin/+ mice and in the 
AOM-DSS model, tumor size (Fig. 2f,g) and proliferation (Fig. 2h and Supplementary Fig. 
3c) were reduced in Nfatc3∆IEC mice as compared to that in their WT littermates, whereas the 
severity of colitis in the AOM-DSS model was not affected (Supplementary Fig. 3d). 
Consistent with these observations, transduction of tumors with an adenoviral construct 
encoding calcineurin-independent, constitutively active NFATc3 (Ad-NFATC3CA increased 
tumor growth in Cnb1∆IEC;ApcMin/+ mice (Fig. 2i and Supplementary Fig. 3e,f). Ad-
NFATC3CA transduction did not further promote tumor growth in Cnb1WT;ApcMin/+ mice (Fig. 
2i), consistent with the idea that constitutive tumor-associated activation of NFATc3 occurs in 
the presence of functional calcineurin (Fig. 2e). 
Because the reduction in tumor size was more pronounced in Cnb1∆IEC mice than in 
Nfatc3∆IEC mice (Figs. 1b,e and 2f,g) and because a reduction in tumor multiplicity was not 
observed in Nfatc3∆IEC mice (Supplementary Fig. 3g,h), we investigated the role of other 
NFAT factors in intestinal tumor development. Deletion of Nfatc1 in intestinal epithelial cells 
(using villin-Cre;Nfatc1fl/fl;ApcMin/+ mice) did not affect tumor multiplicity or size, whereas 
tumor development in mice with a combined IEC-specific deletion of Nfatc1 and Nfatc3 was 
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indistinguishable from that in Nfatc3∆IEC mice (Supplementary Fig. 3i and data not shown 
(K.P.)). Because a compensatory increase in Nfatc2 expression was detected in tumors from 
Nfatc3∆IEC mice (Supplementary Fig. 3j), we considered the possibility that abrogation of 
NFAT-dependent tumor development may require the combined inhibition of all calcineurin-
dependent NFAT factors to avoid escape mechanisms. We therefore treated ApcMin/+ mice 
with adenoviruses expressing VIVIT (Ad-VIVIT; Supplementary Fig. 4a), a peptide 
(MAGPHPVIVITGPHEE) that interferes with calcineurin-dependent activation of NFAT15. 
Ad-VIVIT treatment resulted in reduced tumor size, multiplicity and proliferation, and it 
increased tumor apoptosis (Fig. 2j and Supplementary Fig. 4b,c)—findings that resembled 
observations in Cnb1∆IEC;ApcMin/+ mice. Together, these studies suggest that calcineurin 
promotes intestinal tumor development through the activation of NFAT. In contrast, 
calcineurin did not affect epithelial NF-κB and STAT3 signaling (Supplementary Results 
and Supplementary Fig. 5). 
Microbiota-dependent activation of epithelial calcineurin 
We next aimed to determine the factors responsible for the activation of calcineurin and 
NFAT in intestinal tumors. Mutations in APC, TP53 (which encodes the tumor suppressor 
protein p53) and the KRAS oncogene contribute to human CRC development, and Ras, as well 
as mutant p53, can activate NFAT16–18. Furthermore, noncanonical Wnt signaling and growth 
factors can promote the activation of NFAT19–22. However, we did not find evidence for a role 
of canonical or noncanonical Wnt signaling, p53, Ras or growth factor signaling in the 
activation of tumor-associated calcineurin (Supplementary Results and Supplementary 
Figs. 6 and 7). 
Recent work has revealed a central role of the microbiota, and its TLR-dependent 
recognition, in intestinal tumor development in humans23–26 and rodents27–32. In the ApcMin/+ 
model, TLR-induced Myd88 signaling in the nonhematopoietic compartment30, and 
specifically in the IECs33, regulates tumor growth through control of epithelial proliferation 
and apoptosis30,32. Accordingly, antibiotic treatment34 and germ-free (GF) rederivation28,31 
inhibit intestinal tumor development in ApcMin/+ mice. TLR agonists have been shown to 
activate calcineurin and NFAT in dendritic cells35, so we investigated whether signaling by 
TLR2 and TLR4, the TLRs most strongly induced in ApcMin/+ tumors (Supplementary Fig. 
8a) and expressed by primary human CRC cells36 and SW707 CRC cells (data not shown 
(K.P.)), promotes the activation of tumor-associated calcineurin. Stimulation of TLR4, and to 
a lesser extent TLR2, led to a sustained increase in intracellular Ca2+ (Fig. 3a), an increase in 
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the DNA binding activity of NFAT (Fig. 3b), nuclear translocation of ectopically expressed 
NFATc3 fused to green fluorescent protein (NFATc3–GFP) (Fig. 3c) and NFAT-dependent 
transcription in human CRC cells (Fig. 3d). The TLR-induced increase in the DNA-binding 
activity of NFAT was inhibited by small hairpin RNA (shRNA)-mediated knockdown of 
PPP3R1, chelation of extracellular Ca2+ by EGTA, the use of Ca2+-free medium, and 
chemical inhibition of calcium release–activated channels (CRACs) by 3,5-
bis(trifluoromethyl)pyrazole (BTP) 2 and of phospholipase C by U73122 (Fig. 3e,f and 
Supplementary Fig. 8b). These results suggest that TLR stimulation promotes store-operated 
calcium entry, nuclear NFAT translocation and NFAT-dependent transcription in CRC cells. 
Because TLR agonists can activate calcineurin and NFAT in CRC cells, we next 
assessed the role of TLR signaling in calcineurin-dependent tumor development. Exposure to 
lipopolysaccharide (LPS) increased the proliferation of human CRC cells in a calcineurin- and 
NFATc3-dependent manner (Fig. 3g). Similarly, LPS promoted the growth and proliferation 
of organoids from tumors of Cnb1WT;ApcMin/+ but not Cnb1∆IEC;ApcMin/+ mice (Fig. 3h and 
Supplementary Fig. 8c) through TLR4 (Supplementary Fig. 8d). We therefore investigated 
whether the microbiota and its recognition by TLRs are required for calcineurin-dependent 
tumor growth in vivo. To this end, ApcMin/+ mice were either crossed with mice deficient in 
Myd88 or treated with antibiotics (Supplementary Fig. 8e)—both of which are associated 
with decreased intestinal tumor growth in mice with a loss of functional APC5,30,32,34. Myd88-
deficiency or antibiotic treatment (Supplementary Fig. 8f) prevented nuclear translocation of 
NFATc3 in ApcMin/+ tumors (Fig. 4a) and reduced NFAT-dependent transcription in tumors 
from Cnb1WT;ApcMin/+ but not Cnb1∆IEC;ApcMin/+ mice (Fig. 4b). Moreover, antibiotic 
treatment reduced tumor multiplicity and size in Cnb1WT;ApcMin/+ but not Cnb1∆IEC;ApcMin/+ 
mice (Fig. 4c,d), which could be restored by transduction with Ad-NFATC3CA (Fig. 2i, right 
and Supplementary Fig. 8g). Together, these data demonstrate that the microbiota and its 
Myd88-dependent recognition are sufficient for activation of calcineurin in CRC cells in vitro 
and are required for calcineurin-dependent tumor development in vivo. 
Impaired barrier function in mice harboring intestinal tumors (Supplementary Fig. 
9a)5, perturbation of microbial stratification associated with intestinal tumors 
(Supplementary Fig. 9b and refs. 5,23–25) and increased TLR expression by tumor cells 
(Supplementary Fig. 8a and ref. 36) provide a mechanistic explanation for the pronounced 
activation of the calcineurin-NFAT pathway in tumors, as compared to that in healthy 
intestinal epithelium. Furthermore, differences in community structure (Fig. 4e) but not 
richness (Wilcoxon test P = 0.27 for Chao1 species-richness measure) of the transcriptionally 
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active mucosa-adherent microbiota were observed between intestinal tumors and matched 
normal mucosa of ApcMin/+ mice. Among the major species-level operational taxonomic units 
(OTUs) (average relative abundance >0.5%), six differed between the microbiota associated 
with normal tissues compared to tumors from ApcMin/+ mice (Fig. 4f). Notably, the OTUs that 
were increased in abundance in the tumor-associated microbiota belong to genera known to 
signal via TLR4 and Myd88—such as Escherichia and/or Shigella37, as well as Citrobacter38. 
These alterations on genus level also correspond to increased abundance of 
Enterobacteriaceae and Proteobacteria on family and phylum level, respectively (Fig. 4g). 
These data raise the possibility that, in addition to impaired bacterial stratification, specific 
alterations in bacterial communities may contribute to the TLR-dependent activation of 
calcineurin in intestinal tumors. This is further supported by findings obtained after antibiotic 
treatment (Supplementary Results and Supplementary Fig. 9c–f). Notably, the IEC-specific 
deletion of Ppp3r1 did not affect the community structure of the commensal microbiota (Fig. 
4e, Supplementary Results and Supplementary Fig. 10). As such, calcineurin does not 
regulate tumor development through effects on the composition of the commensal microbiota 
but rather through control of the epithelial response to tumor-associated changes in microbial 
stratification and composition. In addition, Fusobacterium nucleatum (a bacterium that 
promotes intestinal tumor development25,29) and endogenous damage-associated molecular 
pattern molecules (such as the TLR4 ligand high-mobility group box 1 (HMGB1) and the 
HMGB1-binding receptor for advanced glycation end products (RAGE)) did not contribute to 
calcineurin-dependent regulation of intestinal tumor development (Supplementary Results 
and Supplementary Fig. 11). 
 
Calcineurin regulates tumor stem cell function 
We next studied the molecular mechanisms of calcineurin- and NFAT-dependent tumor 
development. Because we did not observe any indirect effects of epithelial calcineurin on 
tumor-infiltrating cells (Supplementary Results and Supplementary Fig. 12a–c), we 
investigated whether calcineurin controls tumor development through direct, NFAT-
dependent transcriptional regulation in tumor cells. Expression of candidate genes previously 
reported to be NFAT dependent—such as Ptgs2 (ref. 10), Myc39, Tp53 (ref. 40), Ccna2 (ref. 
41), Mdm2 (ref. 42), Ddit4 (ref. 13), Pcna12 and Cdkn1a12—did not differ between tumors 
from Cnb1∆IEC;ApcMin/+ mice and Cnb1WT;ApcMin/+ mice (Supplementary Fig. 12d). Because 
tumors from Cnb1∆IEC and Nfatc3∆IEC mice exhibited reduced proliferation (Figs. 1f and 2h) 
and because tumor growth originates from proliferating intestinal stem cells43, which also 
Publisher: NPGNY; Journal: NM: Nature Medicine; Article Type: Article 
 DOI: 10.1038/nm.4072 
Page 8 of 34 
exhibit strong nuclear NFATc3 expression as revealed in mice expressing EGFP under 
control of the leucine-rich repeat-containing G protein–coupled receptor 5 (Lgr5) promoter  
(Lgr5-EGFP-IRES-CreERT2 mice43,44) (Fig. 5a), we investigated the expression of stem cell–
associated genes in tumors from Cnb1∆IEC;ApcMin/+ mice. Expression of Lgr5, olfactomedin 4 
(Olfm4), doublecortin-like kinase 1 (Dclk1), tumor necrosis factor receptor superfamily, 
member 19 (Tnfrsf19) and the CRC-associated variant exon (v) 6 splice variant of CD44 
antigen (Cd44v6; refs. 45,46) were reduced in tumors from Cnb1∆IEC;ApcMin/+ mice (Fig. 
5b,c), antibiotic-treated Cnb1WT;ApcMin/+ but not Cnb1∆IEC;ApcMin/+ mice (Fig. 5b) and Ad-
VIVIT–treated mice (as compared to Ad-LacZ–treated ApcMin/+ mice) (Fig. 5d), and were 
partially reduced in tumors from Nfatc3∆IEC;ApcMin/+ mice (Supplementary Fig. 12e and data 
not shown (K.P.)). In accordance with the tumor-specific activation of calcineurin, normal 
Lgr5+ intestinal stem cells in ApcWT mice showed predominantly cytoplasmic NFATc3 
staining (Supplementary Fig. 12f), which is consistent with unimpaired Lgr5, Olfm4 and 
Dclk1 expression (Supplementary Fig. 12g) and with unaffected proliferation of normal 
IECs in Cnb1∆IEC mice (Supplementary Fig. 2c). 
CD44 is a CRC stem cell marker, whose deletion in ApcMin/+ mice leads to increased 
tumor apoptosis and reduced tumor multiplicity46. Similarly, CD44 splice forms containing 
variant exons, such as Cd44v6, identify human CRC stem cells47, are of negative prognostic 
value in human CRC45 and promote tumor development in the ApcMin/+ model48. Consistent 
with the observation that apoptosis in Cd44-deficient ApcMin/+ tumors predominantly affects 
the stem cell compartment46, reduced numbers of eGFP+ tumor stem cells were detected in 
Lgr5-EGFP-IRES-CreERT2;Cnb1∆IEC;ApcMin/+ mice than in their Cnb1WT littermates (Fig. 5e). 
This reduction in the number of eGFP+ stem cells could be distinguished from a decrease in 
the mean eGFP expression per cell as a consequence of reduced NFAT-dependent activation 
of the Lgr5 promoter (Fig. 5f, for NFAT-dependent Lgr5 transcription see next paragraph). 
Furthermore, consistent with the observation of a reduction in the number of stem cells, 
tumors obtained from Cnb1∆IEC;ApcMin/+ mice gave rise to decreased numbers of organoids, as 
compared to those from Cnb1WT;ApcMin/+ littermates (Fig. 5g). 
The presence of NFAT-binding consensus sites in the promoters of Cd44, Lgr5, Olfm4 
and Dclk1 (Supplementary Fig. 13a–d) and the recent description of NFATc1 binding to 
Lgr5 and Dclk1 in hair follicle stem cells49 further raised the question of whether alterations in 
direct NFAT-dependent transcription contribute to the decreased expression of stem cell–
associated genes in Cnb1∆IEC;ApcMin/+ tumors. Indeed, NFATc3 exhibited calcineurin-
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dependent binding to the promoters of Cd44, Lgr5, Olfm4 and Dclk1 in intestinal tumors in 
vivo, as determined by chromatin immunoprecipitation (ChIP) qPCR analysis (Fig. 5h). 
Moreover, even in eGFP+ stem cells sorted from Cnb1∆IEC;ApcMin/+ tumors, thus avoiding 
indirect effects owing to a loss of stem cells, expression of Cd44v6, Lgr5, Olfm4 and Dclk1 
were reduced as compared to stem cells obtained from Cnb1WT;ApcMin/+ tumors (Fig. 5i). 
Also, shRNA-mediated knockdown of PPP3R1, and to a lesser degree of NFATC3, was 
associated with decreased LGR5 expression in SW707 human CRC cells (Supplementary 
Fig. 13e), whereas CD44, OLFM4 and DCLK1 were not expressed in this cell line. Together 
these data suggest that alterations in direct NFAT-dependent transcription, as well as a loss of 
tumor stem cells, contribute to decreased expression of stem cell–associated genes in 
Cnb1∆IEC;ApcMin/+ tumors. 
Cnb1-deficient ApcMin/+ tumors and SW707 CRC cells showed reduced nuclear β-
catenin expression and decreased T-cell factor (TCF)/lymphoid enhancer factor (LEF)-
dependent transcription (Fig. 5j), respectively, suggesting positive regulation of Wnt 
signaling by epithelial calcineurin. Consistent with the observations that Lgr5 can promote 
canonical Wnt signaling through the binding of R-spondins50 and that the expression of Lgr5 
was reduced in Cnb1-deficient ApcMin/+ tumors (Fig. 5b) and SW707 CRC cells with stable 
knockdown of PPP3R1 (Supplementary Fig. 13e), adenoviral-mediated expression of Lgr5 
in Cnb1∆IEC;ApcMin/+ tumors (Supplementary Fig. 13f) partially restored nuclear β-catenin 
expression (Fig. 5j, left) and clonogenicity, as well as growth, in organoid cultures (Fig. 5j). 
In contrast, Ad-LGR5 transduction had negligible effects on β-catenin expression (Fig. 5j, 
left) and on organoid growth and clonogenicity (Fig. 5j, right) in Cnb1WT;ApcMin/+ mice. 
These results suggest that calcineurin-dependent regulation of Lgr5 expression supports tumor 
stem cell function and contributes, among other pathways, to calcineurin-dependent 
promotion of tumor development. 
NFAT activation is associated with reduced CRC survival 
Calcineurin expression and activity are increased in human CRC51 and the growth of human 
CRC cells in vitro is dependent on calcineurin and NFATc3 (Fig. 3g). This suggests, similar 
to observations in mice, that calcineurin and NFAT regulate human CRC development. To 
further address this question, we investigated whether NFATc3 activation and nuclear 
translocation in human CRC are associated with cancer-related death in individuals with 
CRC. We stained for NFATc3 in CRC samples from 704 individuals for whom survival data 
was available for at least 5 years after diagnosis. In accordance with the observation of 
Publisher: NPGNY; Journal: NM: Nature Medicine; Article Type: Article 
 DOI: 10.1038/nm.4072 
Page 10 of 34 
nuclear NFATc3 translocation in intestinal adenomas of ApcMin/+ mice and thus at early stages 
of the adenoma-carcinoma sequence, nuclear NFATc3 expression was already observed at the 
T1 stage of CRC, with little or no correlation with T (r2 = 0.004, P = 0.01), N (r2 = 0.001, P = 
0.2) and M (r2 = 0.001, P = 0.3) stages or tumor grade (r2 = 0.00001, P = 0.9). However, 
strong nuclear NFATc3 staining (staining score 2–3; n = 593 individuals) was associated with 
reduced survival (analysis limited to death from CRC), as compared to that in individuals 
with little or no nuclear NFATc3 staining (staining score 0–1; n = 111 individuals). These 
results demonstrate that the activation and nuclear translocation of NFATc3 is associated with 
increased death from CRC (Fig. 6a). 
Recent exome and genome sequencing of samples from individuals with CRC 
revealed mutations in protein phosphatase 3 catalytic subunit beta (PPP3CB), which encodes 
the catalytic calcineurin subunit A (CnA)-β, that were associated with reduced CRC 
survival52,53 (http://www.cbioportal.org). Among these variants, PPP3CBR410* is a nonsense 
mutation–containing allele that is predicted to be associated with loss of the autoinhibitory 
domain of CnA-β54. Consistently, ectopic expression of PPP3CBR410* but not of PPP3CBWT 
was associated with constitutive NFAT-dependent transcription in human SW707 CRC cells, 
which was also observed after shRNA-mediated silencing of PPP3R1 (Fig. 6b). As such, 
human CRC is associated with increased calcineurin expression51 and constitutively active 
CnA-β variants (Fig. 6b)52,53, whereas activation of the calcineurin-NFAT pathway is 
associated with increased death from CRC (Fig. 6a). 
DISCUSSION 
Host immunity plays a critical role in the regulation of CRC. In addition to central functions 
of bone marrow–derived innate and adaptive immune cells, immune-associated signaling 
pathways in epithelial cells can promote intestinal tumor development2–6. Here we found that 
calcineurin and NFAT, two members of a pathway involved in immunity, are constitutively 
expressed by IECs and undergo selective activation in tumor tissue as a result of increased 
TLR expression by tumor cells, as well as altered stratification of the tumor-associated 
microbiota. After being activated by microbiota-derived TLR ligands, epithelial calcineurin 
supported the survival and proliferation of tumor stem cells and promoted tumor development 
in an NFAT transcription factor–dependent manner (Fig. 6c). 
These results support a role for microbial elements in the regulation of CRC55,56 and 
provide novel insight into the molecular pathways linking tumor-associated changes in the 
microbiota to oncogenic epithelial signaling. Recent work documented alterations in the 
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composition of the commensal microbiota associated with CRC development, which were 
characterized by an increase in the abundance of bacteria that are known to promote tumor 
growth23,25,29,56,57. Tumor-promoting alterations in microbial composition thereby act together 
with defects in epithelial barrier function5 and microbial stratification5,23–25 to enhance tumor 
growth in a manner dependent on signaling pathways in myeloid and epithelial cells5,24,30,33. 
Using ApcMin/+ mice as a model of genetically driven intestinal tumor formation, we found 
bacterial translocation into intestinal adenomas, as well as an increase in the relative 
abundance of bacteria known to signal via TLR4 and Myd88. This suggests that defects in 
microbial stratification, as well as specific alterations in the composition of the commensal 
microbiota, contribute to the activation of oncogenic epithelial calcineurin. Notably, 
alterations in the tumor-associated microbiota were observed regardless of the IEC-specific 
deletion of calcineurin. This demonstrates that epithelial calcineurin does not regulate 
intestinal tumor development through effects on the composition of the commensal 
microbiota but rather through control of the epithelial response to changes in microbial 
composition and stratification along the adenoma-carcinoma sequence. In conclusion, these 
studies describe a novel epithelial pathway that integrates signals derived from the commensal 
microbiota to promote intestinal tumor development and that may be amenable to therapeutic 
targeting. 
 
METHODS 
Methods and any associated references are available in the online version of the paper. 
 
 
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. 
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Editorial summary 
AOP: The intestinal microbiota signals through epithelial cells to activate calcineurin and NFAT, driving 
proliferation of cancer stem cells and the development of colorectal cancer. 
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Figure 1  Intestinal epithelial calcineurin promotes intestinal tumor development. (a–e) 
Number of total (a,d) and large (b,c,e) tumors in the small intestine of 18-week-old 
Cnb1∆IEC;ApcMin/+ (n = 30) and Cnb1WT;ApcMin/+ (n = 24) littermates (a,b), the small intestine 
of 18-week-old Cnb1ind∆IEC;ApcMin/+ (n = 9) and Cnb1WT;ApcMin/+ (n = 11) littermates after 
tamoxifen treatment (c), and the large intestine of Cnb1∆IEC (n = 16) and Cnb1WT (n = 13) 
mice in the AOM-DSS model (d,e). (f,g) Quantification of cells staining positive for Ki-67 (f, 
left) or cleaved caspase-3 (cCasp-3) (g, left), using immunofluorescence, and representative 
images showing staining for Ki-67 (green) (f, middle and right), cleaved caspase-3 (green) (g, 
middle and right) and DAPI (blue) in tumors from the small intestines of 18-week-old 
Cnb1WT;ApcMin/+ (middle, n = 21 for Ki-67, n = 14 for cCasp-3) and Cnb1∆IEC;ApcMin/+ (right, 
n = 11 for Ki-67, n = 12 for cCasp-3) mice. Scale bars, 100 µm. The combined results of two 
(d,e) or three (c) independent experiments, or nine independent litters (a,b,f,g), are shown. In 
a–g, dots represent individual mice and bar indicates median. P values were calculated using 
the Mann-Whitney U-test.  
Figure 2  Calcineurin regulates tumor development through NFAT. (a) Representative 
images showing staining of the indicated NFAT family members in samples from humans 
with CRC (NFATc1, n = 28; NFATc2, n = 28; NFATc3, n = 704; NFATc4, n = 28). Arrows 
indicate tumor-infiltrating cells, which are delineated from tumors by dashed lines. Scale bar, 
100 µm. (b) Representative western blot analysis (of two independent experiments) for NFAT 
transcription factors in human CRC cell lines. β-actin was used as a loading control. (c) qPCR 
analysis for Nfatc3 expression in tumors (n = 10) or normal tissue (n = 10) from the small 
intestine of ApcMin/+ mice. (d) Representative immunohistochemical analysis (of three 
independent experiments) for expression of NFATc1 (top left), NFATc2 (top right), NFATc3 
(bottom left) and NFATc4 (bottom right) in tumors from the small intestine of ApcMin/+ mice. 
Scale bar, 100 µm. (e) Representative immunofluorescence analysis (of three independent 
experiments) of NFATc3 (green) and DAPI (blue) in the normal mucosa (top) or tumors 
(bottom) of the small intestine of Cnb1WT;ApcMin/+ (left) or Cnb1∆IEC;ApcMin/+ (right) mice. 
Scale bars, 100 µm. (f,g) Number of large tumors in the small intestine of 18-week-old 
Nfatc3∆IEC;ApcMin/+ (n = 23) and Nfatc3WT;ApcMin/+ (n = 25) mice (f) or in the large intestine of 
AOM-DSS-treated Nfatc3∆IEC (n = 30) and Nfatc3WT (n = 39) mice (g). (h) Quantification of 
Ki-67+ cells (left) and representative images for Ki-67 (green) and DAPI (blue) staining 
(middle and right) in tumors from the small intestine of Nfatc3WT;ApcMin/+ (n = 9, middle) and 
Nfatc3∆IEC;ApcMin/+ (n = 6, right) mice. Scale bar, 100 µm. (i,j) Number of large (i,j, left) or 
total (j, right) tumors in the small intestine of Cnb1WT;ApcMin/+ mice (i,j) and 
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Cnb1∆IEC;ApcMin/+ littermates (i) after administration of Ad-NFATC3CA (i), Ad-VIVIT (j) or 
Ad-LacZ (i,j) with or without antibiotics (i, see method section). i: from left to right n = 9, 10, 
7, 9, 6, and 12 mice. j: each diagram from left to right n = 11, 12 mice. In g,i,j, combined data 
for three (g), four (j) and six (i) independent experiments are shown. In all graphs, dots 
represent individual mice; bar indicates median. P values were calculated using the Mann-
Whitney U-test. 
Figure 3  TLR stimulation promotes NFAT activation in CRC. (a,b) Representative calcium 
flux analysis (a) and electrophoretic mobility shift assays (EMSAs) for NFAT and/or NF-κB 
DNA-binding activity (b) in SW707 human CRC cells in response to agonists of TLR2 
(Pam3CSK4), TLR3 (Polyinosinic-polycytidylic acid, pIpC), TLR4 (LPS), TLR5 (flagellin) 
and TLR9 (Escherichia coli DNA). (c) Representative images of live-cell tracking analysis 
for ectopically expressed NFATc3–GFP in SW707 cells before (left) and 20 min after (right) 
LPS treatment. Scale bar, 1 µm. (d) Firefly luciferase expression, normalized to control 
Renilla luciferase expression, in SW707 cells after transfection of NFAT- or NF-κB–
dependent luciferase reporter plasmids and in response to the indicated TLR agonists (each n 
= 3 cultures). Data are mean ± s.e.m. P values were calculated by one-way analysis of 
variance (ANOVA) followed by Dunnett’s test. (e,f) Representative EMSA analysis for 
NFAT DNA-binding activity in nuclear fractions of SW707 cells (e) or SW707 cells stably 
expressing a PPP3R1-specific shRNA or a nontargeting control (scramble) shRNA (f). (g) 
Time course for proliferation of SW707 cells stably expressing a PPP3R1-specific or 
NFATC3-specific shRNA, or a nontargeting control (scramble) shRNA in the presence of 
LPS or vehicle (veh) (each n = 3 cultures). Data are mean ± s.e.m. P value was calculated by 
Student’s t-test. (h) Representative images (left and middle) and quantification (right) of large 
organoids obtained from tumors of Cnb1∆IEC;ApcMin/+ (n = 10 for vehicle, n = 9 for LPS 
treatment) and Cnb1WT;ApcMin/+ mice (n = 9 for vehicle, n = 10 for LPS treatment)  after in 
vitro treatment with vehicle (left) or LPS (middle) for 7 d. Circles in graph indicate individual 
organoid cultures; bar indicates median. Scale bar, 100 µm. P values were calculated by the 
Kruskal-Wallis test followed by Dunn’s test. Data in a–h are representative of three 
independent experiments.  
Figure 4  Calcineurin-mediated tumor development is dependent on the microbiota. (a) 
Representative immunofluorescence images (of three independent experiments) for NFATc3 
(green) and DAPI (blue) in tumors of the small intestine of ApcMin/+ mice (top and bottom left) 
that were treated with vehicle (veh) (top left) or antibiotics (Abx) (bottom left) and Myd88–/–
;ApcMin/+ mice (top right). Bottom right, quantification of NFATc3 nuclear translocation using 
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the Pearson correlation coefficient for ApcMin/+ mice with vehicle (n = 5),  ApcMin/+  mice with 
Abx (n = 11) and  Myd88–/–;ApcMin/+ mice (n = 5). P values were calculated by the Kruskal-
Wallis test followed by the Dunn’s test. Scale bars, 100 µm. (b) Luciferase expression, 
normalized to protein concentration, in tumors in the small intestine of Cnb1WT;ApcMin/+ mice 
administered Ad-LacZ (n = 8) or Ad-NFAT-Luc and treated with vehicle (water, n = 6) or 
antibiotics (n = 5) and Cnb1∆IEC;ApcMin/+ mice treated with vehicle (n = 8) or antibiotics (n = 
5) for 14 weeks (Online Methods). (c,d) Quantification of total (c) and large (d) tumors in the 
small intestine of Cnb1WT;ApcMin/+ mice after treatment with antibiotics (n = 13) or vehicle (n 
= 8) and Cnb1∆IEC;ApcMin/+ mice after treatment with antibiotics (n = 14) or vehicle (n = 10) 
for 14 weeks.In a–d, bar indicates the median and dots represent individual mice. Combined 
results of two (a,b) or four (c,d) independent experiments are shown. P values in b–d were 
calculated by the Mann-Whitney U-test. (e) Constrained analysis of principle coordinates 
(“capscale”, CAP)58  based on Bray-Curtis distances for Cnb1WT;ApcMin/+ mice (n = 7 for 
normal and tumor) and Cnb1∆IEC;ApcMin/+ mice (n = 8 for normal and tumor). CAP1 separates 
normal intestinal mucosa (blue) and tumors (brown, adonis P = 0.003) but not genotypes 
(filled dots and circles; P > 0.05 in analysis of dissimilarity, “adonis”); MDS1 represents first 
non-constrained axis after controlling the effect of tissues. (f) Species-level OTUs with 
differences between normal (n = 7) and tumor tissue (n = 7) of ApcMin/+ mice. The six OTUs 
with significant differences (Wilcoxon test P < 0.05 after correction for multiple testing59) 
that were identified among the major OTUs (average relative abundance >0.5%) comprise 
Prevotella (top left), Lactobacillus (top middle), Escherichia and Shigella (top right), 
Tannerella (bottom left), Parabacteroides (bottom middle) and Citrobacter (bottom right). * 
indicates P < 0.05 in the Wilcoxon test after correction for multiple testing; boxes represent 
the 50% confidence interval and error bars the 95% confidence interval of the relative 
abundance, with the line in the box representing mean value. (g) Relative abundance of 
Proteobacteria (left) and Enterobacteriaceae (right) in normal (n = 7) and tumor tissue (n = 7) 
of ApcMin/+ mice. Matched normal and tumor mucosa are shown in e–g.  
Figure 5  Calcineurin and NFATc3 regulate cancer stem cells. (a) Representative 
immunofluorescence images (of three independent experiments) for NFATc3 (red), Lgr5–
eGFP (green) and DAPI (blue) in tumors from Lgr5-EGFP-IRES-CreERT2;ApcMin/+ mice. 
Scale bar, 100 µm. (b) qPCR analysis for expression of the indicated genes in intestinal 
tumors from Cnb1WT;ApcMin/+ without (n = 7) or with antibiotics (n = 7)  and from 
Cnb1∆IEC;ApcMin/+ mice without (n = 5) or with antibiotics (n = 3). (c) Representative 
immunohistochemistry images (of three independent experiments) for DCLK1 in intestinal 
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tumors from Cnb1WT;ApcMin/+ (left) and Cnb1∆IEC;ApcMin/+ (right) mice. Scale bar, 100 µm. (d) 
qPCR analysis for the expression of the indicated genes in the intestinal tumors from ApcMin/+ 
mice after administration of Ad-LacZ (n = 6) or Ad-VIVIT (n = 6) (Online Methods). (e,f) 
Relative numbers of eGFP+ cells (e) or the geometric mean of eGFP expression among gated 
eGFP+ cells (f) in intestinal tumors from Cnb1∆IEC;ApcMin/+ (n = 7) and Cnb1WT;ApcMin/+ 
littermates (n = 16) on the Lgr5-EGFP-IRES-CreERT2 background. (g) Quantification of 
organoids derived from tumors of Cnb1WT;ApcMin/+ (n = 9) and Cnb1∆IEC;ApcMin/+ mice (n = 
10) (h) qPCR analysis for expression of the indicated genes after NFATc3 ChIP in intestinal 
tumors from Cnb1WT;ApcMin/+ (n = 5) and Cnb1∆IEC;ApcMin/+ mice (n = 5). (i) qPCR analysis 
for expression of the indicated genes in sorted eGFP+ cells from intestinal tumors from 
Cnb1WT;ApcMin/+ (n = 10) and Cnb1∆IEC;ApcMin/+ mice (n = 4) that were on the Lgr5-EGFP-
IRES-CreERT2 background. (j) Representative immunohistochemistry images of β-catenin in 
intestinal tumors from Cnb1WT;ApcMin/+ (left) and Cnb1∆IEC;ApcMin/+ (right) mice after 
administration of Ad-LacZ (top) or Ad-LGR5 (bottom) (Online Methods). Left graph shows 
normalized expression of firefly luciferase after transfection of a TCF-LEF–dependent firefly 
luciferase construct and a control Renilla luciferase construct into SW707 cells stably 
expressing a PPP3R1-specific shRNA (n = 3) or a nontargeting control (scramble) shRNA (n 
= 3). Middle and right graphs show the number of total (middle) or large (right) organoids 
derived from tumors of Ad-LacZ–treated or Ad-LGR5–treated Cnb1∆IEC;ApcMin/+ and 
Cnb1WT;ApcMin/+ littermates (n = 8 for each group). Scale bar, 100 µm. Combined results of 
two (d–f,i) or three (b,h) independent experiments, or results representative of three 
independent experiments (a,c,g,j), are shown, with dots representing individual mice (b,d–
f,h,i), organoid cultures (g,j middle and right graphs) or triplicate cultures (j, left graph). Bar 
indicates the mean (j left graph) or median (b,d–j, middle and right graphs). The Mann-
Whitney U-test (d–i), the Student’s t-test (j, left graph) or the Kruskal-Wallis test followed by 
Dunn’s test (b,j middle and right graphs) were used to calculate P values.  
Figure 6  Activation of NFATc3 is associated with increased death from CRC. (a) Top left: 
Kaplan-Meier analysis of the survival (death from CRC) of individuals with CRC, plotted 
according to the nuclear staining intensity of NFATc3 in CRC tissue. Right: Representative 
immunohistochemistry images of nuclear NFATc3 staining and scoring. Bottom left, 
quantification of CRC tissues according to the intensity of NFATc3 nuclear staining (0 (n = 
16), 1 (n = 95), 2 (n = 412) and 3 (n = 181)). Arrows indicate stromal cells; arrowheads 
indicate tumor cells. Scale bar, 100 µm. The P value was calculated by the log-rank test. (b) 
Firefly luciferase expression, normalized to that of Renilla luciferase, after transfection of an 
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NFAT-dependent firefly luciferase construct and either constructs expressing WT or mutant 
CnA-β or the empty plasmid (pcDNA3.1) into SW707 cells that were stably expressing a 
PPP3R1-specific shRNA (right) or a nontargeting control shRNA (left) (n = 7 for each 
group). Dots represent individual cell cultures. Bar indicates the median. P values were 
calculated by the Mann-Whitney U-test. The results are representative of three independent 
experiments. (c) Schematic summary. In normal epithelium (left), limited TLR expression60,61 
and separation of the luminal microbiota from IECs62 prevents microbiota-induced 
calcineurin-dependent NFAT signaling. In intestinal tumors (right), increased TLR 
expression36, dysbiosis23,25,63 and impaired stratification of the luminal microbiota5,25 allows 
for TLR-dependent, store-operated calcium entry via calcium release activated channels 
(CRACs). This leads to calcium-dependent calcineurin activation and NFAT-dependent 
transcription of stem cell–associated genes, which promote tumor proliferation and prevent 
apoptosis. AMPs, antimicrobial peptides; ER, endoplasmic reticulum; PLC-γ, phospholipase 
C gamma; MAMPs, microbe-associated molecular patterns; STIM1, stromal interaction 
molecule 1; IP3, inositol 1,4,5-trisphosphate.  
ONLINE METHODS 
Mice. 
Mice were handled, and all experiments were performed, in accordance with institutional 
guidelines and with the approval of the Ministerium für Energiewende, Landwirtschaft, 
Umwelt und ländliche Räume des Landes Schleswig-Holstein (Kiel, Germany) and the 
Harvard Medical Area Standing Committee on Animals (Boston, MA, USA). Mice were 
housed in a specific pathogen–free (SPF) barrier facility and were on C57BL/6J background, 
unless mentioned otherwise. GF C57BL/6J mice were housed at gnotobiotic facilities at the 
Max Planck Institute of Evolutionary Biology (Plön, Germany) and the Hannover Medical 
School (Hannover, Germany). Mice carrying loxP-flanked (‘floxed’) alleles of Ppp3r1 (ref. 
64), Nfatc1 (ref. 65), and Nfatc3 (ref. 66) were previously described, and these were crossed 
with ApcMin/+ mice14 (Jackson Laboratory, Bar Harbor, Maine) and either villin-Cre67 
(Jackson Laboratory) or villin-CreERT2 (ref. 68) (gift of Dr. Sylvie Robine, Paris, France) 
mice as described. Myd88–/– mice69 (gift of S. Akira, Osaka, Japan) were crossed with ApcMin/+ 
mice as indicated. Ager-/-;ApcMin/+ mice (hereafter referred to as RAGE-KO mice) have been 
described before70. For Cnb1 deletion in adult mice, Cnb1ind∆IEC mice received 1 mg of 
tamoxifen by intraperitoneal (i.p.) injection on five consecutive days at 12, 14, and 16 weeks 
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of age, and the mice were sacrificed at 18 weeks of age. Lgr5-EGFP-IRES-CreERT2 mice 
have been described before44. 
Animal studies were conducted in a gender- and age-matched manner using littermates 
for each experiment. Where indicated, mice were individually housed after weaning (3 weeks 
of age). Both male and female mice were used, and a formal process of randomization for 
treatment allocation was not performed. The number of animals used per group was based on 
previous experimental results and the observed variability. Macroscopic and microscopic 
tumor analysis was performed in a blinded manner (also see the section on ‘Mouse tumor 
analysis and colitis studies’). For all other in vitro and in vivo analyses, investigators were not 
blinded to treatment allocation. Exclusion of animals from analyses by predefined criteria was 
not applied. 
Mouse tumor analyses and colitis studies. 
Mice on the ApcMin/+ background were sacrificed at week 6 for the analysis of microadenomas 
or at week 18 in all other experiments, unless mentioned otherwise. AOM-DSS studies were 
performed as described previously3 with minor modifications. AOM (Sigma-Aldrich, 
Hamburg, Germany) was administered by i.p. injection at 12.5 mg per kg body weight 
(mg/kg). After 5 d, mice received 2.5% DSS (MP Biomedicals, Eschwege, Germany) in 
autoclaved water for 5 d followed by recovery on autoclaved water for 14 d. Three DSS 
cycles were performed. The disease activity index was determined as described before71. 
Histopathological scoring of tumors and inflammation72 in H&E-stained sections was 
performed by a board-certified pathologist (C.R.), who was blinded to the genotype and 
experimental conditions of the samples. 
Mouse antibiotic, adenoviral, antibody and inhibitor treatment. 
Antibiotic treatment of mice was performed by supplementation of drinking water with 
ampicillin (1 mg/ml), gentamicin (1 mg/ml), metronidazole (1 mg/ml), neomycin (1 mg/ml), 
and vancomycin (0.5 mg/ml) according to ref. 73. For long-term antibiotic treatment, drinking 
water supplemented with antibiotics was continuously provided to mice from the age of 4 
weeks until sacrifice at the age of 18 weeks. 
Adenoviral (Ad5) constructs expressing constitutively active NFATc3 (Ad-CMV-
NFATC3CA)74, luciferase under control of a minimal promoter containing nine NFAT binding 
sites (Ad-NFAT-Luc)75, and LacZ (Ad5-CMV-AdLacZ)76 were obtained from Seven Hills 
Bioreagents (Cincinnati, OH, USA). Ad-LGR5 was obtained from Vector Biolabs 
(Philadelphia, PA, USA). Ad5-CMV-VIVIT77 was a gift from C.M. Norris (Lexington, KY, 
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USA). Adenoviruses were prepared as described previously78. For adenovirus titering, the 
Adeno-X Rapid Titer Kit (Clontech, Saint-Germain-en-Laye, France) was used according to 
the manufacturer’s instructions. For analysis of the restoration of tumor growth by Ad-CMV-
NFATC3CA or Ad-LacZ, mice received 3 × 109 adenoviruses by weekly i.p. injection from 
weeks 12 to 17. For analysis of the effects of Ad-VIVIT and Ad-LacZ on tumor multiplicity, 
tumor growth, tumor proliferation, tumor apoptosis, and RNA expression, mice received 3 × 
109 adenoviruses by weekly i.p. injection from weeks 4 to 17. For analysis of tumor-
associated luciferase expression, mice received 3 × 109 Ad-NFAT-Luc or Ad-LacZ viruses by 
i.p. injection for three consecutive days before tumor extraction. For restoration of LGR5 
expression in intestinal tumors, mice received 3 × 109 Ad-LacZ or Ad-LGR5 virus by i.p. 
injection daily for five consecutive days. Twenty-four hours after the final adenovirus 
administration, tumors were harvested for organoid generation. 
Antibodies specific for mouse high-mobility group box 1 (HMGB1) protein (DPH1.1) 
or the HMGB1 domain BoxA were obtained from HMGBiotech (Milan, Italy). For in vivo 
blocking, mice received 200 µg anti-HMGB1 or isotype control by i.p. injection, or 400 µg 
recombinant BoxA protein or vehicle control by i.p. injection. Tumors were analyzed 8 h after 
injection. 
Fecal microbial transfer. 
For microbial reconstitution of GF mice, 6-week-old WT C57BL/6J mice received fecal 
material obtained from individually housed Cnb1∆IEC;ApcMin/+ or Cnb1WT;ApcMin/+ mice. Stool 
pellets were freshly dissolved in PBS with 0.05% L-cysteine hydrochloride (Sigma-Aldrich; 4 
pellets per 5 ml of PBS) and mice received 100 µl of solution by gavage. After 3 weeks, mice 
were investigated in the AOM-DSS protocol as outlined in the section ‘Mouse tumor analyses 
and colitis studies’. For microbial reconstitution of ApcMin/+ mice, 4-week-old mice were 
treated with antibiotics (see ‘Mouse antibiotic, adenoviral, antibody and inhibitor treatment’) 
for 3 weeks, followed by gavage of fecal microbiota as described above. Mice were sacrificed 
at 18 weeks of age for tumor analyses. 
Mouse intestinal organoids, adenovirus treatment and TLR blocking. 
Intestinal organoids were obtained as described previously79 with minor modifications. 
Briefly, tumors were separated from surrounding normal tissue, washed in PBS ten times, 
incubated in 2 mM EDTA (Life Technologies) in PBS for 30 min, passed through a 70-µm 
cell strainer, and seeded into Matrigel (BD Biosciences, Heidelberg, Germany) with growth 
medium containing advanced Dulbecco’s modified Eagle’s medium–nutrient mixture F12 
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(DMEM/F12; Life technologies), 1× Glutamax (Life technologies), 1M HEPES (Life 
Technologies), penicillin-streptomycin (Biochrom, Berlin, Germany), 1× N2 supplement 
(Life Technologies), 1× B27 supplement (Life Technologies), 1.25 mM N-acetylcysteine 
(Sigma-Aldrich), 50 ng/µl epidermal growth factor (EGF; Life Technologies) and 20% 
conditioned supernatant containing noggin. For organoid preparation from ApcWT tissue, 20% 
conditioned supernatant containing R-spondin was further added. For adenovirus treatment, 
crypt cells were incubated at 37 °C with Ad-LacZ, Ad-VIVIT or Ad-CMV-NFATC3CA for 6 h 
at a multiplicity of infection of 100 before seeding into Matrigel. For blocking of HMGB1 
and TLR4, organoids were treated with 10 µg/ml anti-HMGB1 antibody (DPH1.1), 10 µg/ml 
anti–mouse TLR4 (MTS510, BioLegend) antibody or isotype control antibody, or 10 µg/ml 
BoxA or vehicle control for 7 d, with a change of medium every 2 d. 
Cell culture, lentiviral shRNA transduction and human CnA variants. 
HT-29, Caco-2, HCT-15, HCT-115, HCT-116, SW707, SW480, LoVo, Colo 320, and Jurkat 
cells were cultured in RPMI-1640 medium with 10% FBS (FBS). MODE-K and CMT-93 
cells were cultured in DMEM with 10% FBS. All cell lines were obtained from the American 
Type Culture Collection (ATCC) (LGC Standards GmbH, Wesel, Germany), unless otherwise 
mentioned. YAMC, IMCE, and IMCE-Ras cell lines (see ref.80) were generated and 
generously provided by Dr. Robert H. Whitehead (Nashville, TN, USA) and were cultured as 
previously described80. MODE-K cells were generated and generously provided by 
Dominique Kaiserlian (Lyon, France)81. None of the cell lines mentioned above belong to 
those commonly misidentified (International Cell Line Authentication Committee (ICLAC); 
http://iclac.org/databases/cross-contaminations/). Authentication of commercially available 
cell lines was performed by the ATCC. Cell lines not commercially available were obtained 
from the primary investigators who generated the respective cell lines and were thus not 
authenticated further. For serum starvation, cells were washed twice with PBS and incubated 
with growth medium (see above), with or without FBS for 2 h before cell harvesting, and 
luciferase analysis was performed as described below. For analysis of cell growth, 5 × 103 
cells were seeded in 24-well plates (Greiner Bio One, Frickenhausen, Germany), and cells 
were counted every 2 d. All cell lines repeatedly tested negative for mycoplasma 
contamination in routine screenings. 
SW707 cells were transduced with lentiviruses expressing an shRNA directed against 
human PPP3R1 (TRCN0000002758), NFATC3 (TRCN0000014532) or a nontargeting 
control (nonmammalian shRNA control) (all from Sigma-Aldrich) at a multiplicity of 
infection of 5 in the presence of polybrene (8 µg/µl). Stably transduced cells were cloned 
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using cloning cylinders, and clones were selected based on target gene knockdown as 
determined by quantitative PCR and reduced expression of an NFAT-dependent luciferase 
construct. 
The open reading frame of human CnA (PPP3CB), with or without PPP3CB variants 
identified in CRC52,53 (http://www.cbioportal.org), was synthesized (GeneCust, Luxembourg) 
and subcloned into pcDNA3.1. 
Calcium-flux measurements. 
Calcium-flux measurements were performed using a FlexStation 3 microplate reader 
(Molecular Devices, Biberach, Germany) 24 h after cells were plated in a 96-well flat-bottom 
plate. Calcium-loading dye (FLIPR Calcium 5 Assay Kit, Molecular Devices) was added 
according to the manufacturer’s instructions with 1 h of incubation at 37 °C. Cells were then 
stimulated with Pam3CSK4 (10 µg/ml), LPS (1 µg/ml) or PMA (50 ng/ml) and ionomycin (1 
mM). 
Western blotting, nuclear extracts and electrophoretic mobility shift assays 
(EMSAs). 
Western blotting, nuclear extracts, and EMSAs were performed as described previously82. For 
EMSAs, probes were used that contain an NFAT–AP-1 consensus site (5′-
CAAAAGGCGGAAAGAAACAGTCATTTC-3′) or an NF-κB consensus site (5′-
AGTTGAGGGGACTTTCCCAGGC-3′). For EMSA and western blotting, cells were 
stimulated for 4 h with 1 µg/ml LPS (Sigma-Aldrich), 10 µg/ml Pam3CSK4 (InvivoGen, 
Toulouse, France), 100 µg/ml pIpC (InvivoGen), 10 µg/ml zymosan (InvivoGen), 10 µg/ml 
flagellin (InvivoGen), 100 µg/ml E. coli DNA (InvivoGen) or 50 ng/ml PMA (Sigma-
Aldrich) and 1 mM ionomycin (Sigma-Aldrich). Where indicated, cells were incubated for 2 h 
with 2 mM EGTA (Life Technologies), 5 µM BTP2 (Merck Millipore, Darmstadt, Germany) 
or 10 µM U73122 (Sigma-Aldrich). For ERK1-ERK2 activation, the indicated cell lines were 
serum-starved for 2 h and treated with EGF or vascular endothelial growth factor (VEGF) at 
10 ng/ml (PeproTech, Hamburg, Germany) for the indicated periods. Where indicated, 
YAMC, IMCE and IMCE-Ras cells were incubated at 33 °C with Ad-LacZ, Ad-VIVIT or Ad-
CnCA (truncated and constitutively active CnA-β) at a multiplicity of infection of 50 before 
further treatment or analysis. For western blotting, the following antibodies were used: anti–
human and mouse NFATc1 (7A6, 1:200, Santa Cruz, Heidelberg, Germany), anti–human and 
mouse NFATc2 (4G6G5, 1:200, Santa Cruz), anti–human and mouse NFATc3 (M75 or F1, 
1:200, Santa Cruz), anti–human and mouse NFATc4 (H74, 1:200, Santa Cruz), anti–human 
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and mouse ERK1-ERK2 (137F5, 1:1,000, Cell Signaling Technology, Leiden, The 
Netherlands), anti–human and mouse phospho–ERK1-ERK2 (D13.14.4E, 1:1,000, Cell 
Signaling Technology), anti–human and mouse β-actin (A2066, 1:2,000, Sigma-Aldrich), 
anti–human and mouse Cnb1 (C0581, 1:3,000, Sigma-Aldrich), anti–human and mouse 
STAT3 (79D7, 1:1,000, Cell Signaling Technology), anti–human and mouse phospho-STAT3 
(Y705, 1:1,000 Cell Signaling Technology), and anti–human and mouse Sp1 (ABE135, 
1:1,000, Merck Millipore). 
Luciferase assays. 
For luciferase assays in cultured cell lines, plasmids expressing firefly luciferase under control 
of a minimal NFAT-dependent promoter83 (11783, Addgene, Cambridge, MA, USA), a TCF-
LEF–dependent promoter84 (TOPFlash, 12456, Addgene) or a NF-κB–dependent promoter 
(Promega, Mannheim, Germany) were transfected, along with a plasmid expressing Renilla 
luciferase (phRluc, Promega) for normalization of transfection efficacy, into cells. Where 
indicated, WT or mutated PPP3CB or an empty pcDNA3.1 was transfected along with the 
plasmids described above. 24 h after transfection with Lipofectamine 2000 (Life 
Technologies), according to the manufacturer’s instructions, cells were stimulated using 1 
µg/ml LPS (Sigma-Aldrich), 10 µg/ml Pam3CSK4 (InvivoGen), 100 µg/ml pIpC 
(InvivoGen), 10 µg/ml flagellin (InvivoGen), 100 µg/ml E. coli DNA (InvivoGen), 10 µg/ml 
cyclosporine A (Sigma-Aldrich), 400 ng/ml recombinant Wnt3a (R&D Systems, Minneapolis, 
MN, USA) or 50 ng/ml PMA (Sigma-Aldrich) and 1 µM ionomycin (Sigma-Aldrich). 16 h 
after stimulation, luciferase expression was analyzed with the Dual-Glo-Luciferase Assay 
System (Promega) according to the manufacturer’s instructions using a FlexStation 3 
(Molecular Devices). 
For luciferase analysis in tumor tissues, mice were injected daily for three consecutive 
days with 3 × 109 adenoviruses expressing NFAT-dependent firefly luciferase (Ad-NFAT-
Luc75, Seven Hills Bioreagents, Cincinnati, OH, USA) or Ad-LacZ in 100 µl PBS by i.p. 
injection. 24 h after the last injection, tumors were extracted, washed in PBS and lyzed in 
passive lysis buffer (Promega). Protein concentration was determined, using protein assay dye 
reagent (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer’s 
instructions and used for normalization of luciferase activity. 
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Immunohistochemistry (IHC), immunofluorescence and tissue microarrays 
(TMAs). 
Immunohistochemistry and immunofluorescence stainings were performed using paraffin-
embedded tissues. Antigen retrieval was performed in citrate buffer (1.8% 0.1 M citric acid, 
8.2% 0.1 M sodium citrate) for 25 min at 95 °C; sections were washed in PBS, incubated for 
10 min in H2O2 (for IHC), blocked in 1% BSA in PBS–Tween 20, incubated for 1 h at room 
temperature in primary antibody, and washed in PBS. For immunohistochemistry, sections 
were incubated in EnVision secondary antibody (Dako, Hamburg, Germany) for 30 min at 
room temperature (RT), washed, counterstained with hemalaun and embedded using Entellan 
(Merck Millipore). For immunofluorescence, sections were incubated with Alexa Fluor 488– 
or Alexa Fluor 594–conjugated secondary antibodies (Life Technologies) and DAPI (1 µg/ml, 
Sigma Aldrich) for 1 h at RT, washed, and embedded using FluorSave (Merck Millipore). For 
immunohistochemistry, the following antibodies were used: anti–mouse Cnb1 (C-0581, 
1:500, Sigma-Aldrich), anti–human and mouse NFATc1 (7A6, 1:100, Santa Cruz), anti–
human and mouse NFATc2 (HPA024369, 1:60, Sigma-Aldrich), anti–human and mouse 
NFATc3 (HPA023844, 1:60, Sigma-Aldrich), anti–human and mouse NFATc4 (HPA031641, 
1:60, Sigma-Aldrich), anti–human and mouse NF-κB (C22B4, 1:50, Cell Signaling 
Technology), anti–human and mouse phospho–NF-κB (S276, 1:50, Cell Signaling 
Technology), anti–human and mouse STAT3 (79D7, 1:50, Cell Signaling Technology), anti–
human and mouse phospho-STAT3 (Y705, 1:100, Cell Signaling Technology), anti–human 
and mouse DCLK1 (ab31704, 1:1,000, Abcam, Cambridge, UK), anti–human and mouse β-
catenin (9587, 1:1,000, Cell Signaling Technology), and Envision anti–rabbit IgG and anti-
mouse IgG  (Dako). For immunofluorescence, the following antibodies were used: anti–
human and mouse NFATc3 (F1, 1:50, Santa Cruz), anti–human and mouse NFATc3 
(HPA023844, 1:60, Sigma-Aldrich), anti–human and mouse Ki-67 (D3B5, 1:400, Cell 
Signaling Technology), anti–human and mouse cleaved caspase-3 (D175, 1:300, Cell 
Signaling Technology), anti–lysozyme C (C-19, 1:50, Santa Cruz), anti-GFP (D5.1, 1:75, Cell 
Signaling Technology) and anti-FLAG (M2, 1:10,000, Sigma-Aldrich). Images were taken 
using a Zeiss Axioplan 2 (Carl Zeiss, Jena, Germany). 
Tissue microarrays included matched normal mucosa and CRC samples from 704 
individuals with CRC for whom survival data was available for at least 5 years following 
diagnosis. Studies were approved by the ethics committee of the University Medical Center 
Schleswig-Holstein, Kiel, Germany, and all subjects provided written informed consent. 
Survival analysis is based on centralized recordings by the State of Schleswig-Holstein 
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(Krebsregister Schleswig-Holstein), which also records the cause of death. Individuals with 
non-CRC–related death during follow-up were excluded from this study. NFATc3 staining 
was performed in a standardized manner for all TMAs using the same protocol and a similar 
antibody lot: antigen retrieval was performed using 10 mM citrate buffer (pH 6.0) and a 
DakoCytomation Pascal pressure chamber (DakoCytomation, Hamburg, Germany) at 125 °C 
for 1 min. After a blocking step with Hydrogen Peroxide Block (Thermo Scientific) and Ultra 
V Block (Thermo Scientific), samples were incubated with anti–human and mouse NFATc3 
(HPA023844, 1:60, Sigma-Aldrich) at 4 °C overnight followed by detection using Histofine 
simple stain MAX PO Multi detection reagent (Nichirei Biosciences Inc., Tokyo, Japan) in 
combination with the DAB Peroxidase Substrate Kit (Vector Laboratories Inc., Burlingame, 
USA). Counterstaining was done with haematoxylin (Dr. K. Hollborn & Söhne GmbH & Co 
KG, Leipzig, Germany). Cytoplasmic and nuclear staining intensities of NFATc3 were 
separately scored on a scale from 0 to 3 in a blinded manner, and the following categories 
were assigned (for examples of staining intensity, please refer to Fig. 6a): 0, no expression; 1, 
weak expression; 2, moderate expression; 3, strong expression. 
For analysis of barrier dysfunction, mice were orally administered 0.6 mg per g body 
weight of FITC-dextran (4 kDa, Sigma-Aldrich) in 100 µl PBS, and blood was collected after 
4 h. Relative fluorescence units were measured in serum using a FlexStation 3 microplate 
reader (Molecular Devices). For staining, small intestines were embedded in Tissue-Tek 
O.C.T. compound (Sakura, Alphen aan den Rijn, the Netherlands), and sections were 
prepared using a Leica CM1850 (Leica Biosystems, Wetzlar, Germany). Sections were 
directly incubated with DAPI (1 µg/ml, Sigma-Aldrich) for 10 min at room temperature, 
washed, and embedded using FluorSave (Merck Millipore). 
For senescence-associated staining, the Senescence β-galactosidase Staining Kit (Cell 
Signaling) was used according to the manufacturer’s instructions. Sections of unfixed small 
intestines, embedded in Tissue-Tek O.C.T. compound, were used. 
Live-cell imaging. 
For live-cell imaging, SW707 human CRC cells were transfected, using Lipofectamine 2000 
according to the manufacturer’s instructions (Life Technologies), with a construct expressing 
an NFATc3-GFP fusion protein15 (21664, Addgene). 24 h after transfection, cells were 
stimulated with 1 µM LPS, and images were acquired using an FV1000 confocal laser-
scanning microscope (Olympus, Hamburg, Germany) equipped with a U Plan S Apo 60× oil-
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immersion objective (numerical aperture (N.A.) 1.40) and Olympus Fluoview Software 
(3.0a). 
Fluorescence in situ hybridization. 
For fluorescence in situ hybridization, tissues were incubated in Carnoy’s fixative (46% 
ethanol, 46% glacial acetic acid, 8% chloroform) overnight and embedded in paraffin. Slides 
were incubated at 50 °C for 1 h with hybridization buffer (18% 5 M NaCl, 2% 1 M Tris-HCl 
pH 7.4, 0.5% SDS) and 25 ng of Cy3-labeled universal bacterial probe (Bact338, see 
Supplementary Table 1 for nucleotide sequence; Eurofins, Ebersberg Germany), washed for 
5 min in washing buffer (900 mM NaCl, 2% 1 M Tris-HCl pH 7.4, 0.06% SDS), and 
incubated with DAPI (1 µg/ml, Sigma Aldrich) for 5 min. 
Flow cytometry and flow sorting. 
Flow cytometry was performed as described previously85. Briefly, tumors were excised, 
washed in PBS and incubated in Hank’s balanced salt solution (HBSS, Biochrom) with 1 
mg/ml collagenase D (Biochrom), 20 ng/ml DNase (Roche, Mannheim, Germany) and 50 
µg/ml dispase II (Roche) for 30 min at 37 °C. Cells were passed through a 70-µm cell strainer 
(BD Biosciences), washed in PBS and incubated in FcR blocking reagent (Miltenyi Biotec, 
Bergisch Gladbach, Germany) in 0.5% BSA (SERVA Electrophoresis, Heidelberg, Germany) 
and 2 mM EDTA (Life Technologies) in PBS for 10 min at 4 °C. Fixable viability dye eFluor 
450 (eBiosciences, Frankfurt, Germany) was added to all stainings for exclusion of dead cells, 
and cells were stained with monoclonal antibodies for 20 min at 4 °C. All antibodies were 
purchased from BioLegend (Fell, Germany), except for anti-CD8 (BD Biosciences). For the 
detection of iNKT cells, staining with PBS57-loaded CD1d tetramers (60 min, 4 °C, NIH 
Tetramer Core Facility, Atlanta, USA) was performed. Data were collected using a BD 
Biosciences FACSVerse and were analyzed using FlowJo (Tree Star Inc., Ashland, OR). 
For sorting of eGFP+ stem cells, cells were extracted as mentioned above. After 
passage through a 70-µm cell strainer, cells were incubated in 3 ml TrypLE (Life 
Technologies) including 2,000 U/ml DNase (Sigma-Aldrich) for 30 min at 37 °C, passed 
through a 40-µm cell strainer and then sorted using a BD FACSAria (BD Biosciences). 
RNA extraction and quantitative PCR. 
RNA of tissue was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany). 2 µg 
RNA were transcribed into cDNA using the High-Capacity cDNA Reverse-Transcription Kit 
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(Life Technologies) and quantitative PCR was performed as described previously78. PCR 
primers are listed in Supplementary Table 1. 
RNA from the sorted cells was extracted using the Arturus PicoPure RNA Isolation 
Kit (Life Technologies) according to the manufacturer’s instructions. 
Chromatin immunoprecipitation (ChIP). 
Tissue was cross-linked in 1.5% formaldehyde, and chromatin was purified using the 
SimpleChIP Plus Enzymatic Chromatin IP Kit (Cell Signaling Technology) according to the 
manufacturer’s instructions. 10 µg of digested chromatin was incubated overnight at 4 °C 
with 5 µg anti–human and mouse NFATc3 antibody (M75, Santa Cruz) or isotype and were 
subsequently immunoprecipitated with Protein G magnetic beads. DNA was purified and 
analyzed by qPCR. Input chromatin without immunoprecipitation was used for normalization 
in qPCR. PCR primers are listed in Supplementary Table 1. 
16S rRNA sequencing and analysis. 
Transcriptionally active86 members of the mucosa-attached microbiota were analyzed by 
performing 16S rRNA amplicon sequencing using bacterial cDNA as template for PCR. RNA 
was extracted using the AllPrep DNA/RNA Mini Kit (Qiagen). Amplification of the V1-V2 
region of the 16S rRNA gene was performed using the primer pair 27F and 338R with 
flanking multiplex identifier (MID)-adaptors87. Amplicons were sequenced on the Illumina 
MiSeq platform using the MiSeq V3 sequencing kit to produce 300-bp pair-end reads. Fastq 
sequences were merged using FLASH software88, and merged reads were then filtered based 
on quality (>90% of nucleotides must have quality score 30 or higher for every read). 
Chimeras were removed using Uchime v6.0.307 (ref. 89), and each sample was then 
subsequently normalized to 20,000 random reads per sample. Sequences were classified with 
RDP classifier90, and species-level OTUs were clustered de novo using Usearch v6.0.307 (ref. 
91). All taxonomy tables were created using Perl scripts for the follow-up analysis. Statistical 
analysis of alpha-diversity and beta-diversity was carried out using the Vegan92 package in R. 
Statistical analysis. 
For data sets of unknown or skewed distribution, nonparametric statistical analysis was 
performed using the Mann-Whitney U test or, in case of multiple testing, the Kruskal-Wallis 
test followed by the Dunn’s test for multiple comparisons, and individual samples, as well as 
the median, were plotted. In the case of Gaussian distribution, parametric statistical analysis 
was performed using the two-tailed Student’s t-test or, in case of multiple testing, one-way 
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ANOVA, and the mean ± s.e.m. were plotted. For the disease activity index (DAI) analysis, 
the Wilcoxon matched-pairs signed-rank test was applied. For survival analysis, the log-rank 
test was applied. For evaluation of colocalization of DAPI and NFATc3, the Pearson 
correlation coefficient was used. Measures of location and variability, as well as the statistical 
test applied, are indicated for each data set. 
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Supplementary Results 
Calcineurin does not affect tumor-associated activation of NF-κB and STAT3 
While calcineurin can modulate the activation of NF-κB and STAT31,2, two major promoters 
of intestinal tumor development3-9, Cnb1∆IEC;ApcMin/+ tumors exhibited unaltered expression 
of total and phosphorylated STAT3 and NF-κB (Supplementary Fig. 5a–c), unaffected DNA 
binding activity of NF-κB (Supplementary Fig. 5d), and unchanged tumor-associated 
expression of STAT3 and NF-κB target genes (Supplementary Fig. 5e). These results 
suggest that epithelial calcineurin promotes tumor development predominantly through 
NFAT, while the activation of epithelial NF-κB and STAT3 is largely independent of 
calcineurin. 
 
Tumor-associated activation of calcineurin and NFAT is not the consequence of Wnt or 
growth factor signaling 
We aimed to determine the factors responsible for activation of calcineurin and NFAT in 
intestinal tumors. Mutations in APC, TP53, and KRAS contribute to human CRC development 
and Ras as well as mutant TP53 can activate NFAT10-12. However, basal NFAT DNA binding 
activity and NFAT-dependent transcription were low in human CRC cell lines, regardless of 
KRAS and TP53 mutations, and were indistinguishable between WT, ApcMin/+, and Ras-
overexpressing ApcMin/+ mouse IECs13 (Supplementary Fig. 6a–e and data not shown 
(K.P.)). Accordingly, constitutive β-catenin signaling observed in human CRC cell lines with 
truncating APC mutations (Supplementary Fig. 6f) was associated with decreased rather than 
increased calcineurin-dependent NFAT transcription (Supplementary Fig. 6g). Further, 
recombinant Wnt3a promoted canonical Wnt signaling but not NFAT signaling, consistent 
with previous data (Supplementary Fig. 6h).14,15 While non-canonical Wnt signaling by 
Wnt5a can promote the activation of NFAT14,16, Wnt5a shows limited expression in Apc-
deficient intestinal tumors17 and its transgenic expression does not affect tumor multiplicity, 
size or proliferation17. These data suggest that canonical and non-canonical Wnt signaling are 
not sufficient for intestinal tumor-associated activation of NFAT. Similarly, epidermal growth 
factor (EGF), vascular endothelial growth factor (VEGF), and serum, all of which were 
reported to activate NFAT18-20, elicited ERK1-ERK2 phosphorylation but did not affect 
NFAT-dependent transcription in human CRC cells or mouse IECs (Supplementary Fig. 7a–
d and data not shown). 
 
Inhibition of calcineurin-dependent tumor development by antibiotics 
Antibiotic treatment is associated with a substantial reduction in total intestinal bacterial load 
(Supplementary Fig. 8f), which suggests that reduced mucosal levels of TLR agonists may 
contribute to inhibition of calcineurin-dependent tumor growth by antibiotics (Fig. 4c,d). In 
addition, antibiotics may exhibit further inhibitory effects through interference with specific 
bacterial taxa involved in calcineurin-dependent tumor growth. Consistent with the latter, 
OTUs increased in abundance in the tumor-associated microbiota (Fig. 4f) were targeted by 
antibiotics and were either nearly absent or displayed no difference in relative abundance 
between normal and tumor-associated microbiota following antibiotic treatment 
(Supplementary Fig. 9c–e). Antibiotics therefore lead to a reduction in total intestinal 
bacterial load (Supplementary Fig. 8f), substantial alterations in intestinal microbial 
composition across phyla and genera (Supplementary Fig. 9f), and decreased abundance of 
tumor-associated OTUs (Supplementary Fig. 9c–d), all of which is anticipated to contribute 
to reduced calcineurin-dependent tumor development.  
 
Calcineurin does not regulate intestinal microbial composition 
Although the community structure differed between healthy mucosa and tumors (Fig. 4e), 
genotype-dependent differences in the composition and richness of the mucosa-adherent 
microbiota between Cnb1WT;ApcMin/+ and Cnb1∆IEC;ApcMin/+ mice were not observed (Fig. 4e). 
The absence of calcineurin-dependent effects on microbial composition was not the result of 
microbiome convergence in co-housed mice as the community structure of the intestinal 
microbiota as well as intestinal tumor development did not differ between co-housed and 
individually housed mice (Supplementary Fig. 10a–c). Fecal microbiota transfer into 
antibiotic-treated ApcMin/+ mice (Supplementary Fig. 10d) further revealed that tumor 
development in recipients of Cnb1WT;ApcMin/+ donor microbiota did not differ from recipients 
of Cnb1∆IEC;ApcMin/+ donor microbiota (Supplementary Fig. 10e,f). Similar results were 
obtained upon transfer of fecal microbiota from Cnb1WT;ApcMin/+ and Cnb1∆IEC;ApcMin/+ mice 
into germ-free (GF) C57BL/6J recipients (Supplementary Fig. 10g) investigated in the 
AOM-DSS model (Supplementary Fig. 10h,i). Together, these results suggest that epithelial 
calcineurin does not regulate intestinal tumor development through effects on the composition 
of the commensal microbiota but rather through control of the epithelial response to tumor-
associated changes in microbial stratification and composition.  
 
Fusobacterium nucleatum and damage-associated molecular patterns (DAMPs) do not 
contribute to calcineurin-dependent tumor development in vivo 
Fusobacterium nucleatum, a bacterium which promotes intestinal tumor development21,22, 
was present at very low abundance in the mouse models described here (median relative 
abundance=0.18%, average=0.37%) and is thus unlikely to be involved in the activation of 
epithelial calcineurin.  
 
Damage-associated molecular patterns (DAMPs) such as high-mobility group box 1 
(HMGB1) are released by CRC cells and signal via TLR4.23 We therefore investigated 
whether these endogenous TLR agonists contribute to calcineurin activation in intestinal 
epithelial cells. Neutralizing antibodies against TLR4 and HMGB1 as well as the HMGB1 
antagonist BoxA inhibited the growth of Cnb1WT;ApcMin/+ organoids but not of 
Cnb1∆IEC;ApcMin/+ organoids (Supplementary Fig. 11a). While these mechanisms likely 
contribute to the observed impaired growth of Cnb1∆IEC organoids in the absence of 
exogenous TLR ligands (Fig. 3h), HMGB1 neutralization and BoxA did not affect the nuclear 
translocation of NFATc3 in ApcMin/+ tumors in vivo (Supplementary Fig. 11b). Accordingly, 
ApcMin/+ mice deficient in the HMGB1-binding receptor for advanced glycation end products 
(RAGE), which are protected from intestinal tumor development24, showed only a minor 
reduction in nuclear NFATc3 expression in tumors (Supplementary Fig. 11c). As such, 
HMGB1 can promote calcineurin-dependent growth of ApcMin/+ organoids in vitro, but has a 
minor impact on calcineurin and NFAT activation in ApcMin/+ tumors in vivo. 
 
Intestinal epithelial calcineurin does not affect the abundance or function of tumor-
infiltrating immune cells  
NFATc2 in T cells contributes to colitis-associated cancer through the regulation of IL-6 
transcription25, while transgenic NFATc1 expression in the skin supports tumor development 
through immune cell recruitment and IL-6 production.26 We therefore investigated whether 
deletion of intestinal epithelial Cnb1 affects the abundance of tumor-infiltrating immune cells 
or the expression of oncogenic mediators produced by these cells. However, relative and 
absolute numbers of tumor-infiltrating cells as well as the expression of NFATc1-dependent 
oncogenic mediators previously observed in skin tumors26 did not differ between tumors of 
Cnb1∆IEC;ApcMin/+ and Cnb1WT;ApcMin/+ mice (Supplementary Fig. 12a–c). These results 
suggest that regulation of tumor development by intestinal epithelial calcineurin is unlikely to 
reflect an indirect consequence of NFAT-dependent regulation of tumor-infiltrating immune 
cells.   
Supplementary Table 1. Primer and probe sequences.  
Name Sense Antisense 
 
Bact338 
 
5’-GCTGCCTCCCGTAGGAGT-3’ 
 
GFP 
hLGR5  
5’-AGAACGGCATCAAGGTGAAC-3’ 
5’-CCTTCCAACCTCAGCGTCTT-3’ 
5’-TGCTCAGGTAGTGGTTGTCG-3’ 
5’-CCGCAAGACGTAACTCCTCC-3’ 
hNFATC3 5’-GCTCGACTTCAAACTCGTCTT-3’ 5’-GATGCACAATCATCTGGCTCA-3’ 
hPPP3R1 5’-AGCTTGATTTGGACAATTCTGGT-3’ 5’-ACTCAGGCAGAGACATGAACT-3’ 
mBax 5’-TGAAGACAGGGGCCTTTTTG-3’ 5’-AATTCGCCGGAGACACTCG-3’ 
mBcl2 5’-TGATTAGGGTTCCTCCCCTGA-3’ 5’-GAGCTCAGACTCAGCCATCTT-3’ 
mBcl2l1  5’-GGCCTTTTTCTCCTTTGGCG-3’ 5’-GGCCATCCAACTTGCAATCC-3’ 
mBirc2 5’-AAGGCTAGTGCAACAGAAAAGC-3’ 5’-GCCTGTGTTTAAGGCCCTTTC-3’ 
mBirc3  5’-CGTCTGGTTTTCACCCTGGA-3’ 5’-CTTCCTAGGCTCTGAACGCC-3’ 
mBirc5 5’-ACCTGAGTGGCAAGCATTGT-3’ 5’-CTGCTCAGTGTCCCCTTCAG-3’ 
mCcna2 5’-CAAGAGAATGTCAACCCCGAAA-3’ 5’-GGAAGGTCCTTAAGAGGAGCA-3’ 
mCd44v6 5’-AGAAAATTGGACCCCGGAAC-3’ 5’-GAATGACTCTGTGTGGTGGC-3’ 
mCd44v6_ChIP 
mCdkn1a 
5’-CAGTTCCTCCCTAAGATAAGTCC-3’ 
5’-CGGTGTCAGAGTCTAGGGGA-3’ 
5’-TTCCAGTTTCTCCTTTGCCAC-3’ 
5’-AGGATTGGACATGGTGCCTG-3’ 
mCdkn2a 
mChga 
5’-CTTGAGAAGAGGGCCGCAC-3’ 
5’-AAGAAGAGGAGGAGGAAGAGG-3’ 
5’-AATCTGCACCGTAGTTGAGCA-3’ 
5’-CATGTGGGGTCTCCTCTTCA-3’ 
mDclk1  5’-ATCAGTGCACTAGCGGTCG-3’ 5’-ATGGCTGGCTTGCTTATGGA-3’ 
mDclk1_ChIP 5’-AGGCAGGCAATAGTGGGG-3’ 5’-TGAGGAGGAGGAGAAGAAGAAG-3’ 
mDdit4 5’-TCTTGTCCGCAATCTTCGCT-3’ 5’-GGAGGACGAGAAACGATCCC-3’ 
mIl1b 5’-GATGATAACCTGCTGGTGTGTGA-3’ 5’-TTTGTCGTTGCTTGGTTCTCC-3’ 
mIl6 5’-TCTATACCACTTCACAAGTCGGA-3’ 5’-GAATTGCCATTGCACAACTCTTT-3’ 
mLgr5 5’-CCTACTCGAAGACTTACCCAGT-3’ 5’-GCATTGGGGTGAATGATAGCA-3’ 
mLgr5_ChIP 5’-CACTCCCCAAGACCTCAGG-3’ 5’-CAAATTGCGCGCCCAGTG-3’ 
mLyz1 5’-AATGGATGGCTACCGTGGTGT-3’ 5’-TAGTCGGTGCTTCGGTCTC-3’ 
mMcl1 5’-GAGGGGCTGCTTGGAAAGAT-3’ 5’-TGGTCCTAACCCTTTCGGGA-3’ 
mMdm2 5’-GTCTGTGTCTACCGAGGGTG-3’ 5’-TAAGTGTCGTTTTGCGCTCC-3’ 
mMmp7 5’-ACAAAGGACGACATTGCAGG-3’ 5’-AGTGAGTGCAGACCGTTTCT-3’ 
mMuc2 5’-CCTGAAGACTGTCGTGCTGT-3’ 5’-GGGTAGGGTCACCTCCATCT-3’ 
mMyc 5’-TCTCCATCCTATGTTGCGGTC-3’ 5’-TCCAAGTAACTCGGTCATCATCT-3’ 
mNfatc1 5’-TGCCTTTTGCGAGCAGTATCT-3’ 5’-CAGGCAAGGATGGGCTCATAT-3’ 
mNfatc2 5’-GGATCCCCTCCAAGATATGG-3’ 5’-CCCCAGGAACTCCACAGTAG-3’ 
mNfatc3 5’-TGACTTCTCCAGGTGGCTCT-3’ 5’-GAGAGTGGCAAGGAGATTGC-3 
mNfatc4 5’-GAGGAGCCCCTACCAGACTC-3’ 5’-AGGGTCTTCATGGGGATAGG-3’ 
mOlfm4 5’-CTTTTCCACCAGCACACGC-3’ 5’-CACCACGCCACCATGACTAC-3’ 
mOlfm4_ChIP 5’-GGGTCACATGTTCCCGTG-3’ 5’-GGCTTCTTCCCAGAGTCTCA-3’ 
mOsm 5’-ATGCAGACACGGCTTCTAAGA-3’ 5’-TTGGAGCAGCCACGATTGG-3’ 
mPcna 5’-GAGCTTGGCAATGGGAACAT-3’ 5’-GGAGACAGTGGAGTGGCTTTT-3’ 
mPpp3r1exon3 5’-TTTGAGCGTGGAAGAGTTCA-3’ 5’-GAAGTCCACTTCTCCGTTGC-3’ 
mPpp3r1exon5 5’-GGTGGGCAACAATCTGAAAG-3’ 5’-TCCATCTCCATCCTTATCTGC-3’ 
mPtgs2 5’-TGAGCAACTATTCCAAACCAGC-3’ 5’-GCACGTAGTCTTCGATCACTATC-3’ 
mTnfrsf19 5’-AAGCGTGAGTCTGGAGCACA-3’ 5’-AGGAAGAGAATGGCAGCGAAG-3’ 
mTp53 5’-GGCGTAAACGCTTCGAGATG-3’ 5’-CTTCAGGTAGCTGGAGTGAGC-3’ 
mXiap 5’-CGAGCTGGGTTTCTTTATACCG-3’ 5’-GCAATTTGGGGATATTCTCCTGT-3’ 
h, human; m, mouse 
  
Supplementary Figure Legends 
Supplementary Figure 1. Intestinal tumor initiation and growth are dependent on 
intestinal epithelial calcineurin. 
(a,b) IEC-specific deletion of Cnb1 in normal mucosa and small intestinal tumors of 
Cnb1∆IEC;ApcMin/+ mice as determined by qPCR (a) and immunohistochemistry (b). In (b), the 
same tissues are shown at low (left) and high (right) magnification. Arrows indicate Cnb1-
positive cells in lamina propria and tumor-infiltrating stroma in accordance with IEC-specific 
Cnb1 deletion. (c) RNA expression of the indicated genes in normal mucosa of the small 
intestine of Cnb1∆IEC mice and Cnb1WT littermates as determined by qPCR. (d) 
Representative immunofluorescence staining of lysozyme (red) and DAPI (blue) for detection 
of Paneth cells (upper panel) and PAS staining for detection of goblet cells (lower panel) in 
the indicated mice. (e) Representative macroscopic view of intermediate (2 to <3 mm in 
diameter) to large (≥3 mm in diameter) size tumors in the proximal small intestine of the 
indicated mice. Small tumors are not visible at the magnification shown. (f) The number of 
microscopically detected microadenomas in the small intestine of 6-week-old mice of the 
indicated genotype. (g) Upper panel: Schematic overview of experimental procedures. Black 
arrows indicate tamoxifen administration. Lower panel: number of total tumors in the small 
intestine of 18-week-old Cnb1ind∆IEC;ApcMin/+ mice and Cnb1WT;ApcMin/+ littermates after 
tamoxifen treatment as shown in the upper panel. (h) Schematic overview of AOM-DSS 
treatment. (i,j) Histopathological score of colonic inflammation three days after 
discontinuation of DSS (i) as well as body weight (j) in Cnb1∆IEC mice and Cnb1WT 
littermates in the AOM-DSS model. (k) Disease activity index (DAI) of AOM-DSS-treated 
Cnb1∆IEC mice and Cnb1WT littermates. In (a, c, f, g, i) the median of the indicated number of 
mice with dots representing individual mice are shown. Combined results of two (a, c) and 
three (f) independent litters or two (b, d, i–k) and three (g) independent experiments are 
shown. Size bars in Fig. b and d indicate 100 µm. For statistical analysis, the Mann-Whitney 
U-test (Fig. a, c, f, g, i) or the Wilcoxon matched-pairs signed rank test (k) was applied. 
 
Supplementary Figure 2. Intestinal epithelial calcineurin regulates proliferation and 
apoptosis in tumors but not healthy epithelium and does not affect senescence. 
(a) Representative images of cleaved caspase-3 immunofluorescence (green) and DAPI (blue) 
in small intestinal tumors are shown. Percentage of cleaved caspase-3-positive cells in small 
intestinal microadenomas of 6-week-old Cnb1∆IEC;ApcMin/+ mice and Cnb1WT;ApcMin/+ 
littermates. (b) Left panel: Senescence-associated β-galactosidase (SA-β-Gal) activity in small 
intestinal tumors of Cnb1∆IEC;ApcMin/+ mice and Cnb1WT;ApcMin/+ littermates. pH 6 reflects 
SA-β-Gal activity and pH 4 was used as a positive control. Right panel: RNA expression as 
determined by qPCR of Cdkn2a (p16) in small intestinal tumors of Cnb1∆IEC;ApcMin/+ mice 
and Cnb1WT;ApcMin/+ littermates. (c, right) Percentage of Ki-67-positive cells in normal small 
intestinal mucosa of 18-week-old Cnb1∆IEC;ApcWT  mice and Cnb1WT;ApcWT littermates. (c,d) 
Representative immunofluorescence staining of Ki-67 (c, green), cleaved caspase-3-positive 
(d, green) cells, and DAPI (blue) in normal small intestinal mucosa of 18-week-old 
Cnb1∆IEC;ApcWT mice and Cnb1WT;ApcWT littermates. In (a–c) the median of the indicated 
number of mice with dots representing individual mice are shown. Combined results of three 
(a–c) independent litters are shown. Size bars indicate 100 µm. For statistical analysis, the 
Mann-Whitney U-test (Fig. a–c) was applied. 
 
Supplementary Figure 3. NFAT expression and function in intestinal tumor 
development.  
(a) Representative immunofluorescence staining of the indicated NFAT isoforms (green) and 
DAPI (blue) in the healthy small intestine of wildtype mice. Please note that NFATc3 is 
predominantly located in the intestinal epithelium, while NFATc1 is largely restricted to areas 
of lymphoid follicles (arrow), while showing only weak intestinal epithelial staining 
(arrowhead). NFATc2 and NFATc4 were not detected (data not shown). (b) RNA expression 
of the indicated NFAT isoforms in small intestinal tumors of ApcMin/+ mice as determined by 
qPCR. (c) The percentage of Ki-67-positive tumor cells in large intestinal tumors of 
Nfatc3∆IEC and Nfatc3WT mice in the AOM-DSS-model (left) and representative images of Ki-
67 (green) and DAPI (blue) immunofluorescence (right). (d) Histopathological score of 
colonic inflammation three days after discontinuation of DSS (left) and body weight (right) of 
Nfatc3∆IEC and Nfatc3WT littermates in the AOM-DSS model. (e) Schematic overview of Ad-
NFATC3CA or Ad-LacZ administration. Black arrows indicate Ad-NFATC3CA/Ad-LacZ 
administration. (f) Left panel: Immunofluorescence of anti-FLAG staining (green) and DAPI 
(blue) in small intestinal tumors of ApcMin/+ mice after administration of Ad-LacZ or FLAG-
tagged Ad-NFATC3CA. Right panel: RNA expression of Nfatc3 in small intestinal tumors of 
ApcMin/+ mice treated with Ad-NFATC3CA or Ad-LacZ as determined by qPCR. Please note 
that the FLAG staining (left panel) but not Nfact3 expression (right panel) distinguish 
between endogenous and adenovirus-derived NFATc3. (g) Tumor number in the small 
intestine of Nfatc3∆IEC;ApcMin/+ mice and Nfatc3WT;ApcMin/+ littermates. (h) Tumor number in 
the large intestine of Nfatc3∆IEC mice and Nfatc3WT littermates after AOM-DSS treatment. (i) 
Tumor number in the small intestine of Nfatc1∆IEC;ApcMin/+ mice and Nfatc1WT;ApcMin/+ 
littermates. (j) RNA expression of NFAT isoforms in small intestinal tumors of 
Nfatc3∆IEC;ApcMin/+ mice and Nfatc3WT;ApcMin/+ littermates as determined by qPCR. In b–d 
and f–j dots represent individual mice and the bar indicates the median. Combined results of 
two (b, j), nine (i) and fourteen (g) independent litters or three independent experiments (h) 
are shown. Data in (a, c, d, f) are representative of three independent experiments. Size bars 
in (a, c, f) indicate 100 µm. For statistical analysis, the Mann-Whitney U-test (c, d, f–j) or the 
Kruskal-Wallis test followed by the Dunn’s test for multiple comparisons (b) were applied. 
Supplementary Figure 4. Calcineurin regulates intestinal tumor proliferation and 
apoptosis through the activation of NFAT. 
(a) Left panel: Schematic overview of Ad-VIVIT or Ad-LacZ administration. Black arrows 
indicate Ad-VIVIT/Ad-LacZ administration. Right panel: RNA expression of GFP as 
determined by qPCR in small intestinal tumors of ApcMin/+ mice. Due to the short open 
reading frame of VIVIT, which prevents target gene amplification, adenovirus-derived GFP 
was amplified. (b,c) Percentage of Ki-67-positive (b, green) and cleaved caspase-3-positive 
(c, green) cells in ApcMin/+ mice after administration of Ad-VIVIT or Ad-LacZ as described in 
Methods. In (b,c), DAPI is shown in blue. Size bars in (b,c) indicate 100 µm. Dots in (a–c) 
represent individual mice and the bar indicates the median. Combined results of two (a) or 
three (b,c) independent experiments are shown. For statistical analysis, the Mann-Whitney U-
test (a–c) was applied. 
 
Supplementary Figure 5. Intestinal epithelial deletion of Cnb1 in ApcMin/+ mice does not 
affect the expression or function of STAT3 and NF-κB in tumor cells. 
(a) Immunohistochemistry of total and phosphorylated STAT3 and NF-κB in small intestinal 
tumors of Cnb1∆IEC;ApcMin/+ mice and Cnb1WT;ApcMin/+ littermates. (b) Percentage of tumor 
cells positive for phosphorylated STAT3 or NF-κB as determined by immunohistochemistry. 
(c) Western blots of the indicated proteins in small intestinal tumors of Cnb1∆IEC;ApcMin/+ 
mice and Cnb1WT;ApcMin/+ littermates. (d) NF-κB DNA binding activity as determined by 
EMSA in small intestinal tumors of Cnb1∆IEC;ApcMin/+ mice and Cnb1WT;ApcMin/+ littermates. 
(e) RNA expression of target genes of STAT3 (Bcl2l1 (Bcl-XL)4,5,27, Birc5 (survivin)4,27, Bcl2 
28
, Mcl127) and NF-κB (Bcl2 29, Bcl2l1 3,30, Birc2 29, Birc3 29, Xiap 29, Bax 3,31) in small 
intestinal tumors of Cnb1∆IEC;ApcMin/+ mice and Cnb1WT;ApcMin/+ littermates as determined by 
qPCR. Symbols in (b,e) represent individual mice and the bar indicates the median. 
Combined results of two independent litters (b,e) or three independent experiments (c,d) are 
shown. Stainings in (a) are representative of data shown in (b). Size bars in (a) indicate 100 
µm. For statistical analysis, the Mann-Whitney U-test (b, e) was applied. 
 
Supplementary Figure 6. Oncogenic Ras or loss of APC are not sufficient for activation 
of intestinal epithelial NFAT. 
(a) NFAT DNA binding activity as determined by EMSA in SW707 human CRC cells in the 
presence of PMA and ionomycin (Iono) or vehicle. (b) Normalized firefly luciferase 
expression upon transfection of an NFAT-dependent firefly luciferase construct, along with a 
control Renilla luciferase construct, in KRAS-mutant LoVo and TP53-mutant SW707 human 
CRC cells. Cells were treated as indicated with cyclosporine A (CsA) or PMA and ionomycin 
(Iono). Similar results were obtained with TP53-mutant HT-29 and Caco-2 cells (data not 
shown). (c) Luciferase expression upon transfection of an NFAT-dependent firefly luciferase 
construct and a control Renilla luciferase plasmid for normalization into immortalized IECs 
from wildtype mice (YAMC), ApcMin/+ mice (IMCE), and ApcMin/+ IECs overexpressing 
oncogenic Ras (IMCE-Ras)13. (d) NFAT DNA binding activity as determined by EMSA in 
immortalized IECs from wildtype mice (YAMC), ApcMin/+ mice (IMCE) and ApcMin/+ IECs 
overexpressing oncogenic Ras (IMCE-Ras). (e) Western blot of NFATc3 in YAMC, IMCE 
and IMCE-Ras cells after administration of Ad-LacZ, Ad-VIVIT or Ad-CnCA. (f,g) Luciferase 
expression upon transfection of a TCF- and LEF-dependent firefly luciferase construct 
(TOPFlash, f) or an NFAT-dependent firefly luciferase construct (g) along with a control 
Renilla luciferase plasmid for normalization into HCT116 and SW480 human CRC cell lines. 
SW480 cells harbor a truncating APC mutation associated with constitutive β-catenin 
signaling and are compared to HCT116 cells, which do not harbor activating APC mutations. 
Please note the break in the y-axis in f. (h) Normalized firefly luciferase expression upon 
transfection of an NFAT-dependent firefly luciferase construct (right) or TCF- and LEF-
dependent firefly luciferase construct (TOPFlash, left) together with a control Renilla 
luciferase construct into MODE-K cells. Cells were stimulated with recombinant Wnt3a or 
vehicle for 16 hours before the analysis of luciferase expression. Triplicates are shown in (b, 
c, f–h) and the bar indicates the mean. Data are representative of two (d,e) or three (a–c, f–h) 
independent experiments. For statistical analysis, the Student’s t test (b, f–h) or one-way 
ANOVA followed by Dunnett’s test for multiple comparisons (c) were applied. 
 
Supplementary Figure 7.  EGF and VEGF are not sufficient for activation of intestinal 
epithelial NFAT. 
(a–d) Western blots of the indicated proteins (a,b) and luciferase expression following 
transfection of an NFAT-dependent firefly luciferase construct along with a control Renilla 
luciferase construct (c,d) in the indicated cell lines treated with EGF, VEGF, the EGFR 
tyrosine kinase inhibitor AG 1478, or serum starvation. Triplicates are shown in c,d and the 
bar indicates the mean. Data in all panels are representative of three independent experiments. 
For statistical analysis, the Student’s t test (d) was applied. 
 
Supplementary Figure 8. TLR-dependent growth of Cnb1WT ApcMin/+ organoids.  
(a) RNA expression of TLRs in small intestinal tumors of ApcMin/+ mice as determined by 
qPCR. (b) Left: RNA expression of PPP3R1 (Cnb1) in SW707 human CRC cells stably 
expressing shRNA directed against PPP3R1 or a non-targeting control (scramble) as 
determined by qPCR. Right: Western blots of the indicated proteins in SW707 human CRC 
cells stably expressing shRNA directed against PPP3R1 or a non-targeting control (scramble). 
(c) Immunofluorescence staining of Ki-67 (green) and DAPI (blue) in organoids obtained 
from small intestinal tumors of Cnb1∆IEC;ApcMin/+ mice and Cnb1WT;ApcMin/+ littermates. 
Organoids were grown in the presence of LPS or vehicle as indicated. (d) The number of 
large (≥ 300 µm in diameter) organoids after treatment for 7 days with the indicated 
antibodies or TLR agonists. (e) Schematic overview of antibiotic treatment. (f) Expression of 
16S rDNA as determined by qPCR in the stool of ApcMin/+ mice treated with oral antibiotics or 
vehicle for 2 weeks. (g) Schematic overview of antibiotic treatment and Ad-NFATC3CA or 
Ad-LacZ administration. Black arrows indicate Ad-NFATC3CA or Ad-LacZ administration. 
The size bar in (c) indicates 100 µm. Data are representative of two (d) or three (b,c) 
independent experiments. In (a,f) the median of the indicated number of mice (dots represent 
individual mice) based on combined results of two independent litters (a) or two independent 
experiments (f) are shown. Triplicates are shown in (b, left) and the bar indicates the mean. 
For statistical analysis, the Mann-Whitney U-test (a,f), the Student’s t test (b) or the Kruskal-
Wallis test followed by the Dunn’s test for multiple comparisons (d) was applied. 
 
Supplementary Figure 9. Intestinal tumors are associated with epithelial barrier 
dysfunction and impaired bacterial stratification. Antibiotic treatment is associated with 
alterations in the composition of the tumor-associated microbiota. 
(a) Left: FITC-dextran (green) and DAPI (blue) in small intestinal normal mucosa and tumors 
of ApcMin/+ mice. Arrows indicate luminal FITC-dextran in normal intestine. Arrowheads 
indicate FITC-dextran diffusion into tumor tissue. Right: Relative fluorescence units (RFU) in 
serum of 18-week-old ApcWT and ApcMin/+ mice four hours after oral administration of FITC-
dextran. For statistical analysis, the Mann-Whitney U test was applied. (b) Fluorescence in-
situ hybridization with a universal bacterial probe (red) and DAPI counterstaining (blue) in 
normal mucosa and small intestinal tumors of ApcMin/+ mice. Arrows indicate separation of 
luminal bacteria from normal intestinal epithelium. Arrowheads demonstrate loss of this 
stratification and direct microbial exposure in areas of intestinal tumors. (c) Boxplot of six 
species-level OTUs in antibiotic-treated Cnb1WT;ApcMin/+ mice. These OTUs were 
significantly different in relative abundance in healthy compared to tumor tissue of non-
antibiotic Cnb1WT;ApcMin/+ mice (please refer to Fig. 4f). In contrast, after antibiotic 
treatment, as shown here, the respective OTUs were either nearly absent (Prevotella, 
Escherichia or Shigella) or no longer differed in relative abundance between healthy mucosa 
and tumor tissue (Wilcoxon test P>0.05 for all comparisons). (d) Boxplot of the relative 
abundance of the Proteobacteria phylum and Enterobacteriaceae family in antibiotic-treated 
Cnb1WT;ApcMin/+ mice. Both were significantly different in relative abundance in healthy 
compared to tumor tissue in non-antibiotic treated Cnb1WT;ApcMin/+ mice (Fig. 4g), but did not 
differ in relative abundance following antibiotic treatment as shown here (Wilcoxon test of 
normal mucosa-associated compared to tumor-associated microbiota P>0.05). (e) PCoA plot 
of normal mucosa-associated and tumor-associated microbiota in antibiotic-treated 
Cnb1WT;ApcMin/+ mice. After antibiotic treatment, significant differences in the composition of 
the normal mucosa-associated compared to the tumor-associated microbiota were not 
observed (Adonis test p=0.37; compare to Fig. 4e).  (f) Bar plot of the relative abundance of 
major genera and their corresponding phylum in Cnb1WT;ApcMin/+ mice with respect to tumor 
status and antibiotic (Abx) treatment. The ten most abundant genera are plotted for each 
group. Data in (a, left panel; b) are representative of three independent experiments. Results 
in (c-f) are based on ten antibiotic-treated Cnb1WT;ApcMin/+ mice with matched normal and 
tumor mucosa. In (a, right panel) the median of the indicated number of mice (dots represent 
individual mice) based on combined results of two (a) independent experiments is shown. The 
size bars indicate 50 (b) or 100 µm (a).  
 
Supplementary Figure 10. Intestinal epithelial calcineurin does not affect the community 
structure of the intestinal microbiota. 
(a) Constrained analysis of principle coordinates based on Bray-Curtis distances, showing 
tissue type, genotype, and housing conditions. CAP1 significantly separates communities 
between normal intestinal mucosa (blue) versus tumor tissue (brown, adonis P=0.003; left 
panel), but within each tissue type, housing conditions and genotypes, alone as well as 
combined, do not have significant effects on separation of intestinal microbial composition 
(middle and right panel). (b,c) Number of large (≥3 mm in diameter) (b) and total (c) small 
intestinal tumors in 18-week-old Cnb1∆IEC;ApcMin/+ mice and Cnb1WT;ApcMin/+ littermates. 
Mice were individually housed upon weaning or co-housed as indicated. (d) Schematic 
overview of fecal microbiota transfer experiments in the ApcMin/+ model. (e,f) Number of total 
(e) and large (≥3 mm in diameter) (f) tumors in the small intestine of 18-week-old ApcMin/+ 
mice after treatment as shown in (d). (g) Schematic overview of fecal microbiota transfer 
experiments in the AOM-DSS model. (h,i) Number of total (h) and large (≥3 mm in diameter) 
(i) tumors in the large intestine of C57BL/6J mice in the AOM-DSS-model, treated as shown 
in (g). Results in (a) are based on eight Cnb1WT;ApcMin/+ mice and seven Cnb1∆IEC;ApcMin/+ 
mice with matched normal and tumor mucosa. Combined results of several independent litters 
(b,c) or two independent experiments (e,f, h,i) are shown. Each dot represents an individual 
mouse and the bar indicates the median. For statistical analysis, the Mann-Whitney U-test 
(b,c, h,i) or the Kruskal-Wallis test followed by the Dunn’s test for multiple comparisons (e,f) 
was applied. Abx, antibiotic treatment. 
 
Supplementary Figure 11. HMGB1 and RAGE signaling have a minor impact on the 
activation of NFATc3 in ApcMin/+ tumors in vivo. 
(a) Number of large (≥ 300 µm in diameter) organoids obtained from tumors of 
Cnb1∆IEC;ApcMin/+ mice and Cnb1WT;ApcMin/+ littermates after treatment with the indicated 
antibodies or inhibitors for seven consecutive days. (b) Left: NFATc3 (green) and DAPI 
(blue) in small intestinal tumors of ApcMin/+ mice 8 hours after i.p. injection of anti (α)-
HMGB1 or isotype control antibody or BoxA or vehicle control. Right: Pearson correlation 
coefficient for measurement of nuclear co-localization of NFATc3 and DAPI in small 
intestinal tumors of ApcMin/+ mice. (c) Left: NFATc3 (green) and DAPI (blue) in RAGE-
WT;ApcMin/+ and RAGE-KO;ApcMin/+ littermates. Right: Pearson correlation coefficient for 
measurement of nuclear co-localization of NFATc3 and DAPI in small intestinal tumors of 
RAGE-WT;ApcMin/+ and RAGE-KO;ApcMin/+ littermates. Each dot represents individual 
organoid cultures (a) or mice (b,c) and the bar indicates the median. Representative stainings 
of two independent experiments (b,c) are shown. The size bar indicates 100 µm. For 
statistical analysis, the Mann-Whitney U-test (a–c) or the Kruskal-Wallis test followed by the 
Dunn’s test for multiple comparisons (a) was applied. 
 
Supplementary Figure 12. Intestinal epithelial calcineurin and NFAT regulate the 
expression of tumor stem cell-associated genes, but do not affect immune cell 
recruitment to intestinal tumors.  
(a,b) Flow cytometry of intratumoral immune cells. (a) Gating strategy according to 21. (b) 
Percentage of immune cell populations indicated in (a) in small intestinal tumors of 
Cnb1∆IEC;ApcMin/+ mice and Cnb1WT;ApcMin/+ littermates. (c,d) RNA expression as determined 
by qPCR in small intestinal tumors of Cnb1∆IEC;ApcMin/+ mice and Cnb1WT;ApcMin/+ 
littermates. (e) RNA expression as determined by qPCR in small intestinal tumors of 
Nfatc3∆IEC;ApcMin/+ mice and Nfatc3WT;ApcMin/+ littermates. (f) Immunofluorescence staining 
of NFATc3 (red), Lgr5-eGFP (green) and DAPI (blue) in normal small intestinal epithelium 
of Lgr5-EGFP-IRES-creERT2 mice in the absence of tamoxifen treatment. (g) RNA 
expression as determined by qPCR of the indicated target genes in normal small intestinal 
epithelium of Cnb1∆IEC mice and Cnb1WT littermates. Size bars represent 100 µm (f). In (b–e, 
g) combined results of two (b) independent experiments or two (c–e, g) independent litters are 
shown. Data in (f) are representative of three independent experiments. For statistical 
analysis, the Mann-Whitney U-test (b–e, g) was applied. DCs, dendritic cells; MDSCs, 
myeloid-derived suppressor cells; NK cells, natural killer cells; TAMs, tumor-associated 
macrophages. 
 
Supplementary Figure 13. NFAT consensus elements in the promoters of stem cell-
associated genes and calcineurin- and NFATc3-dependent LGR5 expression. 
(a–d) Promoter sequences of mouse Lgr5 (a), Olfm4 (b), Dclk1 (c) and Cd44 (d) contain 
NFAT consensus elements (boxes). Primer used for ChIP-qPCR and the start codon are 
indicated (underlined). (e) RNA expression (left, middle panel) as determined by qPCR of 
LGR5 and NFATC3 and western blot (right panel) of the indicated proteins in human SW707 
CRC cells stably expressing shRNA directed against PPP3R1, NFATC3 or a non-targeting 
control (scramble). (f) RNA expression as determined by qPCR in small intestinal tumors of 
Cnb1∆IEC;ApcMin/+ mice and Cnb1WT;ApcMin/+ littermates. Mice were administered Ad-LacZ or 
Ad-LGR5 by daily i.p. injection for four consecutive days. Tissues were collected 24 hours 
after the last injection. In (f), each dot represents one mouse and the bar indicates the median. 
Combined results of two experiments are shown in (f). In (e), triplicates are shown and the bar 
indicates the mean. The western blot in (e) is representative of three independent experiments. 
For statistical analysis, the Student’s t test (e, middle), one-way ANOVA followed by 
Dunnett’s test for multiple comparisons (e, left) or the Kruskal-Wallis test followed by the 
Dunn’s test for multiple comparisons (f) was applied. 
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